Calithera Biosciences, Inc.
US ˙ OTCPK ˙ US13089P5070

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark N Lampert. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Mark N Lampert has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:EPIX / ESSA Pharma Inc. 10% Owner 560,797
US:KYMR / Kymera Therapeutics, Inc. Director 353,412
10% Owner 62,383
US:XOMA / XOMA Royalty Corporation 10% Owner 1,267,545
US:ALLK / Allakos Inc. 10% Owner 0
US:OLMA / Olema Pharmaceuticals, Inc. Director 347,970
38,961
US:FDMT / 4D Molecular Therapeutics, Inc. 87,911
US: / Third Harmonic Bio, Inc. 176,692
US:MLTX / MoonLake Immunotherapeutics Director, 10% Owner 1,287,768
US:ELDN / Eledon Pharmaceuticals, Inc. 10% Owner 220,460
Director 0
US:PNT / POINT Biopharma Global Inc. 0
US:RPTX / Repare Therapeutics Inc. 10% Owner 548,938
10% Owner 1,204,412
US:CTIC / CTI BioPharma Corp Director, 10% Owner 0
US:GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) 10% Owner 0
US:CGEM / Cullinan Therapeutics, Inc. 10% Owner 64,161
US:VSTM / Verastem, Inc. 10% Owner 10,753,294
US:MRUS / Merus N.V. 10% Owner 232,747
10% Owner 3,372,098
US:INFI / Infinity Pharmaceuticals Inc. 10% Owner 534,847
US:IDYA / IDEAYA Biosciences, Inc. 233,150
US:CTMX / CytomX Therapeutics, Inc. 10% Owner 2,945,743
US:CYTK / Cytokinetics, Incorporated 463,244
10% Owner 3,547
US:CALA / Calithera Biosciences, Inc. 10% Owner 480,432
US:CNCE / Concert Pharmaceuticals Inc 10% Owner 169,589
US:IMDZ / Immune Design Corp. 10% Owner 370,391
US:SNDX / Syndax Pharmaceuticals, Inc. 10% Owner 188,746
US:ARQL / ArQule, Inc. 10% Owner 771,305
US:XENE / Xenon Pharmaceuticals Inc. 10% Owner 238,000
US:RGLS / Regulus Therapeutics Inc. 10% Owner 17,248,837
US:CAPS / Capstone Holding Corp. 890,487
US:NVLS / Nivalis Therapeutics, Inc. 10% Owner 201,811
US:ONTY / Oncothyreon, Inc. Director, 10% Owner 6,197
US:CCXI / ChemoCentryx Inc 0
US:04269XAA3 / Array BioPharma Inc. Bonds 3.0% 6/1/2020 7,058,997
US:LGND / Ligand Pharmaceuticals Incorporated 130,175
US:RGDO / 2,632
US:PTN / Palatin Technologies, Inc. 10% Owner 2,494,521
US:RIGL / Rigel Pharmaceuticals, Inc. 10% Owner 646,559
US:TRGT / Targacept 10% Owner 1,713,907
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark N Lampert. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CALA / Calithera Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2019-11-20 CALA BVF PARTNERS L P/IL 98,518 3.9116 4,926 78.2320 385,363 147 157 387,862 100.65
2019-11-20 CALA BVF PARTNERS L P/IL 79,285 3.9116 3,964 78.2320 310,131
2019-11-20 CALA BVF PARTNERS L P/IL 14,151 3.9116 708 78.2320 55,353
2019-11-14 CALA BVF PARTNERS L P/IL 71,495 3.3700 3,575 67.4000 240,938
2019-11-14 CALA BVF PARTNERS L P/IL 45,888 3.3700 2,294 67.4000 154,643
2019-11-14 CALA BVF PARTNERS L P/IL 11,105 3.3700 555 67.4000 37,424
2019-10-30 CALA BVF PARTNERS L P/IL 408,592 2.7000 20,430 54.0000 1,103,198
2019-10-30 CALA BVF PARTNERS L P/IL 331,048 2.7000 16,552 54.0000 893,830
2019-10-30 CALA BVF PARTNERS L P/IL 57,868 2.7000 2,893 54.0000 156,244
2019-10-29 CALA BVF PARTNERS L P/IL 872,373 2.6000 43,619 52.0000 2,268,170
2019-10-29 CALA BVF PARTNERS L P/IL 610,052 2.6000 30,503 52.0000 1,586,135
2019-10-29 CALA BVF PARTNERS L P/IL 116,552 2.6000 5,828 52.0000 303,035

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CALA / Calithera Biosciences, Inc. Insider Trades
Insider Sales CALA / Calithera Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2020-05-21 CALA BVF PARTNERS L P/IL 1,027,016 6.0000 51,351 120.0000 6,162,096 354 39.2 -4,149,176 -67.33
2020-05-21 CALA BVF PARTNERS L P/IL 1,064,332 6.0000 53,217 120.0000 6,385,992
2020-05-21 CALA BVF PARTNERS L P/IL 192,250 6.0000 9,612 120.0000 1,153,500

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CALA / Calithera Biosciences, Inc. Insider Trades
Insider Purchases CAPS / Capstone Holding Corp. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CAPS / Capstone Holding Corp. Insider Trades
Insider Sales CAPS / Capstone Holding Corp. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2017-07-14 CAPS BVF PARTNERS L P/IL 3,993,637 0.0600 3,994 60.0000 239,618 182 0.0450 -239,438 -99.93
2017-07-14 CAPS BVF PARTNERS L P/IL 242,236 0.0600 242 60.0000 14,534
2017-07-14 CAPS BVF PARTNERS L P/IL 105,713 0.0600 106 60.0000 6,343

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CAPS / Capstone Holding Corp. Insider Trades
Insider Purchases CGEM / Cullinan Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2022-06-01 CGEM BVF PARTNERS L P/IL 405,641 10.9994 405,641 10.9994 4,461,808 48 15.4200 1,793,177 40.19
2022-06-01 CGEM BVF PARTNERS L P/IL 301,009 10.9994 301,009 10.9994 3,310,918
2022-06-01 CGEM BVF PARTNERS L P/IL 44,746 10.9994 44,746 10.9994 492,179
2022-05-13 CGEM BVF PARTNERS L P/IL 53,598 9.1350 53,598 9.1350 489,618
2022-05-13 CGEM BVF PARTNERS L P/IL 38,558 9.1350 38,558 9.1350 352,227
2022-05-13 CGEM BVF PARTNERS L P/IL 17,744 9.1350 17,744 9.1350 162,091
2022-05-12 CGEM BVF PARTNERS L P/IL 542,999 9.0600 542,999 9.0600 4,919,571
2022-05-12 CGEM BVF PARTNERS L P/IL 457,001 9.0600 457,001 9.0600 4,140,429
2022-04-01 CGEM BVF PARTNERS L P/IL 266,598 10.7499 266,598 10.7499 2,865,902
2022-04-01 CGEM BVF PARTNERS L P/IL 9,402 10.7499 9,402 10.7499 101,071

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CGEM / Cullinan Therapeutics, Inc. Insider Trades
Insider Sales CGEM / Cullinan Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CGEM / Cullinan Therapeutics, Inc. Insider Trades
Insider Purchases CTMX / CytomX Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CTMX / CytomX Therapeutics, Inc. Insider Trades
Insider Sales CTMX / CytomX Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CTMX / CytomX Therapeutics, Inc. Insider Trades
Insider Purchases CYTK / Cytokinetics, Incorporated - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2019-12-11 CYTK BVF PARTNERS L P/IL 60,103 9.5150 60,103 9.5150 571,880 217 28.9600 1,168,703 204.36
2019-12-11 CYTK BVF PARTNERS L P/IL 49,804 9.5150 49,804 9.5150 473,885
2019-12-11 CYTK BVF PARTNERS L P/IL 8,506 9.5150 8,506 9.5150 80,935
2019-12-10 CYTK BVF PARTNERS L P/IL 113,529 9.4000 113,529 9.4000 1,067,173
2019-12-10 CYTK BVF PARTNERS L P/IL 95,100 9.4000 95,100 9.4000 893,940
2019-12-10 CYTK BVF PARTNERS L P/IL 15,030 9.4000 15,030 9.4000 141,282

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYTK / Cytokinetics, Incorporated Insider Trades
Insider Sales CYTK / Cytokinetics, Incorporated - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2020-12-09 CYTK BVF PARTNERS L P/IL 239,274 18.0000 239,274 18.0000 4,306,932 217 18.5400 129,208 3.00
2020-12-09 CYTK BVF PARTNERS L P/IL 166,194 18.0000 166,194 18.0000 2,991,492
2020-12-09 CYTK BVF PARTNERS L P/IL 25,486 18.0000 25,486 18.0000 458,748
2020-02-13 CYTK BVF PARTNERS L P/IL 486,344 15.7868 486,344 15.7868 7,677,815
2020-02-13 CYTK BVF PARTNERS L P/IL 510,793 15.7868 510,793 15.7868 8,063,787
2020-02-13 CYTK BVF PARTNERS L P/IL 74,893 15.7868 74,893 15.7868 1,182,321

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CYTK / Cytokinetics, Incorporated Insider Trades
Insider Purchases ELDN / Eledon Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2024-05-09 ELDN BVF PARTNERS L P/IL 1,031,385 1,031,385 176 5.3000
2024-05-09 ELDN BVF PARTNERS L P/IL 821,121 821,121
2024-05-09 ELDN BVF PARTNERS L P/IL 75,431 75,431
2023-05-05 ELDN BVF PARTNERS L P/IL 1,055,445 1,055,445
2023-05-05 ELDN BVF PARTNERS L P/IL 837,146 837,146
2023-05-05 ELDN BVF PARTNERS L P/IL 86,341 86,341

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELDN / Eledon Pharmaceuticals, Inc. Insider Trades
Insider Sales ELDN / Eledon Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ELDN / Eledon Pharmaceuticals, Inc. Insider Trades
Insider Purchases EPIX / ESSA Pharma Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EPIX / ESSA Pharma Inc. Insider Trades
Insider Sales EPIX / ESSA Pharma Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2025-08-05 EPIX BVF PARTNERS L P/IL 79 1.8779 79 1.8779 148 30 0.2316 -130 -87.64
2025-08-05 EPIX BVF PARTNERS L P/IL 66 1.8779 66 1.8779 124
2025-08-05 EPIX BVF PARTNERS L P/IL 11 1.8779 11 1.8779 21

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EPIX / ESSA Pharma Inc. Insider Trades
Insider Purchases FDMT / 4D Molecular Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FDMT / 4D Molecular Therapeutics, Inc. Insider Trades
Insider Sales FDMT / 4D Molecular Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FDMT / 4D Molecular Therapeutics, Inc. Insider Trades
Insider Purchases GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) Insider Trades
Insider Sales GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GPCR / Structure Therapeutics Inc. - Depositary Receipt (Common Stock) Insider Trades
Insider Purchases IDYA / IDEAYA Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2020-06-30 IDYA BVF PARTNERS L P/IL 1,521 13.3164 1,521 13.3164 20,254 279 24.83 17,512 86.46
2020-06-30 IDYA BVF PARTNERS L P/IL 929 13.3164 929 13.3164 12,371
2020-06-30 IDYA BVF PARTNERS L P/IL 81 13.3164 81 13.3164 1,079
2020-06-22 IDYA BVF PARTNERS L P/IL 10,524 13.9347 10,524 13.9347 146,649
2020-06-22 IDYA BVF PARTNERS L P/IL 7,854 13.9347 7,854 13.9347 109,443
2020-06-22 IDYA BVF PARTNERS L P/IL 1,354 13.9347 1,354 13.9347 18,868
2020-06-19 IDYA BVF PARTNERS L P/IL 52,443 14.3895 52,443 14.3895 754,629
2020-06-19 IDYA BVF PARTNERS L P/IL 39,052 14.3895 39,052 14.3895 561,939
2020-06-19 IDYA BVF PARTNERS L P/IL 6,769 14.3895 6,769 14.3895 97,403

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IDYA / IDEAYA Biosciences, Inc. Insider Trades
Insider Sales IDYA / IDEAYA Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2021-02-02 IDYA BVF PARTNERS L P/IL 25,234 18.0000 25,234 18.0000 454,212 359 15.2100 -70,403 -15.50
2021-02-02 IDYA BVF PARTNERS L P/IL 16,850 18.0000 16,850 18.0000 303,300
2021-02-02 IDYA BVF PARTNERS L P/IL 4,325 18.0000 4,325 18.0000 77,850

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IDYA / IDEAYA Biosciences, Inc. Insider Trades
Insider Purchases INFIQ / Infinity Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2018-12-13 INFI BVF PARTNERS L P/IL 54,461 1.1995 54,461 1.1995 65,326 91 1.9100 38,696 59.24
2018-12-13 INFI BVF PARTNERS L P/IL 120,539 1.1995 120,539 1.1995 144,587
2018-11-28 INFI BVF PARTNERS L P/IL 100,000 1.3000 100,000 1.3000 130,000
2018-11-21 INFI BVF PARTNERS L P/IL 4,119 1.3500 4,119 1.3500 5,561
2018-11-21 INFI BVF PARTNERS L P/IL 581 1.3500 581 1.3500 784
2018-11-19 INFI BVF PARTNERS L P/IL 733,151 1.3698 733,151 1.3698 1,004,270
2018-11-19 INFI BVF PARTNERS L P/IL 556,709 1.3698 556,709 1.3698 762,580
2018-11-19 INFI BVF PARTNERS L P/IL 81,648 1.3698 81,648 1.3698 111,841
2018-11-19 INFI BVF PARTNERS L P/IL 50,044 1.3500 50,044 1.3500 67,559
2018-11-19 INFI BVF PARTNERS L P/IL 38,001 1.3500 38,001 1.3500 51,301
2018-11-19 INFI BVF PARTNERS L P/IL 5,573 1.3500 5,573 1.3500 7,524
2018-11-15 INFI BVF PARTNERS L P/IL 52,400 1.3500 52,400 1.3500 70,740
2018-11-15 INFI BVF PARTNERS L P/IL 39,074 1.3500 39,074 1.3500 52,750
2018-11-14 INFI BVF PARTNERS L P/IL 117,290 1.3400 117,290 1.3400 157,169
2018-11-14 INFI BVF PARTNERS L P/IL 92,960 1.3400 92,960 1.3400 124,566
2018-11-13 INFI BVF PARTNERS L P/IL 41,454 1.3500 41,454 1.3500 55,963
2018-11-13 INFI BVF PARTNERS L P/IL 562,754 1.3500 562,754 1.3500 759,718
2018-06-21 INFI BVF PARTNERS L P/IL 230,555 1.6500 230,555 1.6500 380,416
2018-06-21 INFI BVF PARTNERS L P/IL 158,151 1.6500 158,151 1.6500 260,949
2018-06-21 INFI BVF PARTNERS L P/IL 36,825 1.6500 36,825 1.6500 60,761
2018-06-19 INFI BVF PARTNERS L P/IL 1,916,760 1.6500 1,916,760 1.6500 3,162,654
2018-06-19 INFI BVF PARTNERS L P/IL 1,419,907 1.6500 1,419,907 1.6500 2,342,847
2018-06-19 INFI BVF PARTNERS L P/IL 179,893 1.6500 179,893 1.6500 296,823
2018-04-10 INFI BVF PARTNERS L P/IL 546,865 2.0000 546,865 2.0000 1,093,730
2018-04-10 INFI BVF PARTNERS L P/IL 365,682 2.0000 365,682 2.0000 731,364
2018-04-10 INFI BVF PARTNERS L P/IL 97,453 2.0000 97,453 2.0000 194,906
2018-04-09 INFI BVF PARTNERS L P/IL 228,691 1.9000 228,691 1.9000 434,513
2018-04-09 INFI BVF PARTNERS L P/IL 208,872 1.9000 208,872 1.9000 396,857
2018-04-09 INFI BVF PARTNERS L P/IL 62,437 1.9000 62,437 1.9000 118,630
2017-10-04 INFI BVF PARTNERS L P/IL 355,081 1.2840 355,081 1.2840 455,924
2017-10-04 INFI BVF PARTNERS L P/IL 235,326 1.2840 235,326 1.2840 302,159
2017-10-04 INFI BVF PARTNERS L P/IL 63,042 1.2840 63,042 1.2840 80,946
2017-10-03 INFI BVF PARTNERS L P/IL 523,601 1.2350 523,601 1.2350 646,647
2017-10-03 INFI BVF PARTNERS L P/IL 394,078 1.2350 394,078 1.2350 486,686
2017-10-03 INFI BVF PARTNERS L P/IL 28,918 1.2350 28,918 1.2350 35,714
2017-01-03 INFI BVF PARTNERS L P/IL 1,145 1.3397 1,145 1.3397 1,534
2017-01-03 INFI BVF PARTNERS L P/IL 3,234 1.3397 3,234 1.3397 4,333
2016-12-30 INFI BVF PARTNERS L P/IL 2,348 1.3396 2,348 1.3396 3,145
2016-12-30 INFI BVF PARTNERS L P/IL 1,205 1.3396 1,205 1.3396 1,614
2016-12-28 INFI BVF PARTNERS L P/IL 401,726 1.3356 401,726 1.3356 536,545
2016-12-28 INFI BVF PARTNERS L P/IL 260,046 1.3356 260,046 1.3356 347,317
2016-12-28 INFI BVF PARTNERS L P/IL 77,076 1.3356 77,076 1.3356 102,943
2016-12-20 INFI BVF PARTNERS L P/IL 11,646 1.3549 11,646 1.3549 15,779
2016-12-20 INFI BVF PARTNERS L P/IL 8,111 1.3549 8,111 1.3549 10,990
2016-12-20 INFI BVF PARTNERS L P/IL 2,244 1.3549 2,244 1.3549 3,040
2016-12-19 INFI BVF PARTNERS L P/IL 108,202 1.3584 108,202 1.3584 146,982
2016-12-19 INFI BVF PARTNERS L P/IL 69,041 1.3584 69,041 1.3584 93,785
2016-12-19 INFI BVF PARTNERS L P/IL 21,021 1.3584 21,021 1.3584 28,555
2016-12-16 INFI BVF PARTNERS L P/IL 236,393 1.2800 236,393 1.2800 302,583
2016-12-16 INFI BVF PARTNERS L P/IL 150,451 1.2800 150,451 1.2800 192,577
2016-12-16 INFI BVF PARTNERS L P/IL 47,812 1.2800 47,812 1.2800 61,199
2016-12-02 INFI BVF PARTNERS L P/IL 30,998 1.1901 30,998 1.1901 36,891
2016-12-02 INFI BVF PARTNERS L P/IL 18,586 1.1901 18,586 1.1901 22,119
2016-12-02 INFI BVF PARTNERS L P/IL 2,916 1.1901 2,916 1.1901 3,470
2016-12-01 INFI BVF PARTNERS L P/IL 81,276 1.1845 81,276 1.1845 96,271
2016-12-01 INFI BVF PARTNERS L P/IL 52,457 1.1845 52,457 1.1845 62,135
2016-12-01 INFI BVF PARTNERS L P/IL 15,161 1.1845 15,161 1.1845 17,958

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INFIQ / Infinity Pharmaceuticals, Inc. Insider Trades
Insider Sales INFIQ / Infinity Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2021-02-11 INFI BVF PARTNERS L P/IL 1,215,491 5.3686 1,215,491 5.3686 6,525,485 350 1.1100 -5,176,289 -79.32
2021-02-11 INFI BVF PARTNERS L P/IL 892,467 5.3686 892,467 5.3686 4,791,298
2021-02-11 INFI BVF PARTNERS L P/IL 152,127 5.3686 152,127 5.3686 816,709
2021-01-22 INFI BVF PARTNERS L P/IL 2,821,663 4.1388 2,821,663 4.1388 11,678,299
2021-01-22 INFI BVF PARTNERS L P/IL 2,458,838 4.1388 2,458,838 4.1388 10,176,639
2021-01-22 INFI BVF PARTNERS L P/IL 568,019 4.1388 568,019 4.1388 2,350,917

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INFIQ / Infinity Pharmaceuticals, Inc. Insider Trades
Insider Purchases KYMR / Kymera Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2025-06-30 KYMR BVF PARTNERS L P/IL 142,604 44.0000 142,604 44.0000 6,274,576 23 46.4300 346,528 5.52
2025-06-30 KYMR BVF PARTNERS L P/IL 115,783 44.0000 115,783 44.0000 5,094,452
2025-06-30 KYMR BVF PARTNERS L P/IL 58,780 44.0000 58,780 44.0000 2,586,320
2023-11-03 KYMR BVF PARTNERS L P/IL 103,885 14.0689 103,885 14.0689 1,461,548
2023-11-03 KYMR BVF PARTNERS L P/IL 83,708 14.0689 83,708 14.0689 1,177,679
2023-11-03 KYMR BVF PARTNERS L P/IL 10,106 14.0689 10,106 14.0689 142,180
2023-11-02 KYMR BVF PARTNERS L P/IL 57,618 11.6444 57,618 11.6444 670,927
2023-11-02 KYMR BVF PARTNERS L P/IL 132,016 11.6444 132,016 11.6444 1,537,247
2023-11-02 KYMR BVF PARTNERS L P/IL 26,772 11.6444 26,772 11.6444 311,744
2023-01-12 KYMR BVF PARTNERS L P/IL 2,985 31.2426 2,985 31.2426 93,259
2023-01-12 KYMR BVF PARTNERS L P/IL 15,912 31.2426 15,912 31.2426 497,132
2023-01-11 KYMR BVF PARTNERS L P/IL 10,961 29.8869 10,961 29.8869 327,590
2023-01-11 KYMR BVF PARTNERS L P/IL 11,149 29.8869 11,149 29.8869 333,209
2022-08-22 KYMR BVF PARTNERS L P/IL 285,046 26.0000 285,046 26.0000 7,411,196
2022-08-22 KYMR BVF PARTNERS L P/IL 233,362 26.0000 233,362 26.0000 6,067,412
2022-08-22 KYMR BVF PARTNERS L P/IL 27,117 26.0000 27,117 26.0000 705,042
2022-05-27 KYMR BVF PARTNERS L P/IL 35,793 14.7828 35,793 14.7828 529,121
2022-05-27 KYMR BVF PARTNERS L P/IL 26,353 14.7828 26,353 14.7828 389,571
2022-05-27 KYMR BVF PARTNERS L P/IL 3,223 14.7828 3,223 14.7828 47,645
2022-05-26 KYMR BVF PARTNERS L P/IL 123,043 14.2106 123,043 14.2106 1,748,515
2022-05-26 KYMR BVF PARTNERS L P/IL 90,372 14.2106 90,372 14.2106 1,284,240
2022-05-26 KYMR BVF PARTNERS L P/IL 10,642 14.2106 10,642 14.2106 151,229
2022-05-20 KYMR BVF PARTNERS L P/IL 5,883 13.9994 5,883 13.9994 82,358
2022-05-20 KYMR BVF PARTNERS L P/IL 4,180 13.9994 4,180 13.9994 58,517
2022-05-20 KYMR BVF PARTNERS L P/IL 37 13.9994 37 13.9994 518
2022-05-06 KYMR BVF PARTNERS L P/IL 55,210 19.2550 55,210 19.2550 1,063,069
2022-05-06 KYMR BVF PARTNERS L P/IL 40,659 19.2550 40,659 19.2550 782,889
2022-05-06 KYMR BVF PARTNERS L P/IL 4,131 19.2550 4,131 19.2550 79,542
2022-05-05 KYMR BVF PARTNERS L P/IL 75,495 19.5991 75,495 19.5991 1,479,634
2022-05-05 KYMR BVF PARTNERS L P/IL 70,439 19.5991 70,439 19.5991 1,380,541
2022-05-05 KYMR BVF PARTNERS L P/IL 4,066 19.5991 4,066 19.5991 79,690
2022-01-31 KYMR BVF PARTNERS L P/IL 20,085 40.7000 20,085 40.7000 817,460
2022-01-31 KYMR BVF PARTNERS L P/IL 14,323 40.7000 14,323 40.7000 582,946
2022-01-27 KYMR BVF PARTNERS L P/IL 58,042 38.3319 58,042 38.3319 2,224,860
2022-01-27 KYMR BVF PARTNERS L P/IL 37,859 38.3319 37,859 38.3319 1,451,207
2022-01-24 KYMR BVF PARTNERS L P/IL 158,041 37.7635 158,041 37.7635 5,968,181
2022-01-24 KYMR BVF PARTNERS L P/IL 114,726 37.7635 114,726 37.7635 4,332,455
2021-07-01 KYMR BVF PARTNERS L P/IL 304,997 47.0000 304,997 47.0000 14,334,859
2021-07-01 KYMR BVF PARTNERS L P/IL 211,711 47.0000 211,711 47.0000 9,950,417
2021-07-01 KYMR BVF PARTNERS L P/IL 27,458 47.0000 27,458 47.0000 1,290,526

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KYMR / Kymera Therapeutics, Inc. Insider Trades
Insider Sales KYMR / Kymera Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KYMR / Kymera Therapeutics, Inc. Insider Trades
Insider Purchases MLTX / MoonLake Immunotherapeutics - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MLTX / MoonLake Immunotherapeutics Insider Trades
Insider Sales MLTX / MoonLake Immunotherapeutics - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2024-10-04 MLTX BVF PARTNERS L P/IL 1,030,589 50.0016 1,030,589 50.0016 51,531,099 186 32.8350 -17,691,708 -34.33
2024-10-04 MLTX BVF PARTNERS L P/IL 836,862 50.0016 836,862 50.0016 41,844,439
2024-10-04 MLTX BVF PARTNERS L P/IL 132,549 50.0016 132,549 50.0016 6,627,662

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MLTX / MoonLake Immunotherapeutics Insider Trades
Insider Purchases MRUS / Merus N.V. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2021-03-30 MRUS BVF PARTNERS L P/IL 165,000 19.7500 165,000 19.7500 3,258,750 275 32.29 2,069,100 63.49
2021-03-30 MRUS BVF PARTNERS L P/IL 108,106 19.7500 108,106 19.7500 2,135,094
2021-03-30 MRUS BVF PARTNERS L P/IL 26,894 19.7500 26,894 19.7500 531,156
2021-03-22 MRUS BVF PARTNERS L P/IL 71,756 22.7500 71,756 22.7500 1,632,449
2021-03-22 MRUS BVF PARTNERS L P/IL 7,744 22.7500 7,744 22.7500 176,176
2021-03-16 MRUS BVF PARTNERS L P/IL 53,061 22.9996 53,061 22.9996 1,220,382
2021-03-16 MRUS BVF PARTNERS L P/IL 195,768 22.9996 195,768 22.9996 4,502,586
2021-03-16 MRUS BVF PARTNERS L P/IL 1,171 22.9996 1,171 22.9996 26,933
2021-01-21 MRUS BVF PARTNERS L P/IL 457,814 24.7500 457,814 24.7500 11,330,896
2021-01-21 MRUS BVF PARTNERS L P/IL 343,444 24.7500 343,444 24.7500 8,500,239
2021-01-21 MRUS BVF PARTNERS L P/IL 43,422 24.7500 43,422 24.7500 1,074,694
2020-12-18 MRUS BVF PARTNERS L P/IL 114,968 16.0500 114,968 16.0500 1,845,236
2020-12-18 MRUS BVF PARTNERS L P/IL 45,032 16.0500 45,032 16.0500 722,764
2020-09-15 MRUS BVF PARTNERS L P/IL 77,751 11.7500 77,751 11.7500 913,574
2020-09-15 MRUS BVF PARTNERS L P/IL 58,745 11.7500 58,745 11.7500 690,254
2020-09-15 MRUS BVF PARTNERS L P/IL 10,258 11.7500 10,258 11.7500 120,532
2020-09-10 MRUS BVF PARTNERS L P/IL 100,461 11.0982 100,461 11.0982 1,114,936
2020-09-10 MRUS BVF PARTNERS L P/IL 76,374 11.0982 76,374 11.0982 847,614
2020-09-10 MRUS BVF PARTNERS L P/IL 12,816 11.0982 12,816 11.0982 142,235
2020-09-03 MRUS BVF PARTNERS L P/IL 104,827 11.1700 104,827 11.1700 1,170,918
2020-09-03 MRUS BVF PARTNERS L P/IL 82,740 11.1700 82,740 11.1700 924,206
2020-09-03 MRUS BVF PARTNERS L P/IL 14,339 11.1700 14,339 11.1700 160,167
2020-06-08 MRUS BVF PARTNERS L P/IL 46,966 15.2000 46,966 15.2000 713,883
2020-06-08 MRUS BVF PARTNERS L P/IL 33,321 15.2000 33,321 15.2000 506,479
2020-06-08 MRUS BVF PARTNERS L P/IL 6,967 15.2000 6,967 15.2000 105,898
2020-06-01 MRUS BVF PARTNERS L P/IL 806,443 14.0000 806,443 14.0000 11,290,202
2020-06-01 MRUS BVF PARTNERS L P/IL 561,966 14.0000 561,966 14.0000 7,867,524
2020-06-01 MRUS BVF PARTNERS L P/IL 94,101 14.0000 94,101 14.0000 1,317,414
2020-01-16 MRUS BVF PARTNERS L P/IL 146,442 16.1500 146,442 16.1500 2,365,038
2020-01-16 MRUS BVF PARTNERS L P/IL 112,561 16.1500 112,561 16.1500 1,817,860
2020-01-16 MRUS BVF PARTNERS L P/IL 19,727 16.1500 19,727 16.1500 318,591
2020-01-13 MRUS BVF PARTNERS L P/IL 53,448 14.9784 53,448 14.9784 800,566
2020-01-13 MRUS BVF PARTNERS L P/IL 25,108 14.9784 25,108 14.9784 376,078
2020-01-13 MRUS BVF PARTNERS L P/IL 5,406 14.9784 5,406 14.9784 80,973

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRUS / Merus N.V. Insider Trades
Insider Sales MRUS / Merus N.V. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2021-10-08 MRUS BVF PARTNERS L P/IL 80,011 27.7865 80,011 27.7865 2,223,226 230 13.9800 -1,104,671 -49.69
2021-10-08 MRUS BVF PARTNERS L P/IL 58,327 27.7865 58,327 27.7865 1,620,703
2021-10-08 MRUS BVF PARTNERS L P/IL 8,929 27.7865 8,929 27.7865 248,106
2021-10-07 MRUS BVF PARTNERS L P/IL 530,999 27.5311 530,999 27.5311 14,618,987
2021-10-07 MRUS BVF PARTNERS L P/IL 384,914 27.5311 384,914 27.5311 10,597,106
2021-10-07 MRUS BVF PARTNERS L P/IL 69,534 27.5311 69,534 27.5311 1,914,348
2021-07-02 MRUS BVF PARTNERS L P/IL 1,106,478 20.7500 1,106,478 20.7500 22,959,418
2021-07-02 MRUS BVF PARTNERS L P/IL 928,739 20.7500 928,739 20.7500 19,271,334
2021-07-02 MRUS BVF PARTNERS L P/IL 150,805 20.7500 150,805 20.7500 3,129,204

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRUS / Merus N.V. Insider Trades
Insider Purchases OLMA / Olema Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2023-09-12 OLMA BVF PARTNERS L P/IL 775,278 9.8400 775,278 9.8400 7,628,736 57 17.1400 5,659,530 74.19
2023-09-12 OLMA BVF PARTNERS L P/IL 677,853 9.8400 677,853 9.8400 6,670,074
2023-09-12 OLMA BVF PARTNERS L P/IL 52,801 9.8400 52,801 9.8400 519,562
2022-06-10 OLMA BVF PARTNERS L P/IL 158,583 4.0345 158,583 4.0345 639,803
2022-06-10 OLMA BVF PARTNERS L P/IL 41,417 4.0345 41,417 4.0345 167,097
2021-11-30 OLMA BVF PARTNERS L P/IL 362,430 9.3903 362,430 9.3903 3,403,326
2021-11-30 OLMA BVF PARTNERS L P/IL 341,977 9.3903 341,977 9.3903 3,211,267
2021-11-30 OLMA BVF PARTNERS L P/IL 35,268 9.3903 35,268 9.3903 331,177
2020-11-19 OLMA BVF PARTNERS L P/IL 613,918 19.0000 613,918 19.0000 11,664,442
2020-11-19 OLMA BVF PARTNERS L P/IL 446,425 19.0000 446,425 19.0000 8,482,075
2020-11-19 OLMA BVF PARTNERS L P/IL 74,991 19.0000 74,991 19.0000 1,424,829

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OLMA / Olema Pharmaceuticals, Inc. Insider Trades
Insider Sales OLMA / Olema Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OLMA / Olema Pharmaceuticals, Inc. Insider Trades
Insider Purchases RIGL / Rigel Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2013-06-07 RIGL BVF PARTNERS L P/IL 24,598 3.4677 2,460 34.6770 85,298 276 47.5 31,504 36.93
2013-06-07 RIGL BVF PARTNERS L P/IL 8,102 3.4677 810 34.6770 28,095

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RIGL / Rigel Pharmaceuticals, Inc. Insider Trades
Insider Sales RIGL / Rigel Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2013-11-19 RIGL BVF PARTNERS L P/IL 331,566 2.6418 33,157 26.4180 875,931 286 2.6 -789,725 -90.16
2013-11-19 RIGL BVF PARTNERS L P/IL 153,056 2.6418 15,306 26.4180 404,343

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RIGL / Rigel Pharmaceuticals, Inc. Insider Trades
Insider Purchases RPTX / Repare Therapeutics Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2023-11-16 RPTX BVF PARTNERS L P/IL 153,693 5.3837 153,693 5.3837 827,437 88 8.4100 465,121 56.21
2023-11-16 RPTX BVF PARTNERS L P/IL 125,909 5.3837 125,909 5.3837 677,856
2023-11-16 RPTX BVF PARTNERS L P/IL 16,143 5.3837 16,143 5.3837 86,909
2023-11-15 RPTX BVF PARTNERS L P/IL 493,337 4.9999 493,337 4.9999 2,466,636
2023-11-15 RPTX BVF PARTNERS L P/IL 390,507 4.9999 390,507 4.9999 1,952,496
2023-11-15 RPTX BVF PARTNERS L P/IL 47,712 4.9999 47,712 4.9999 238,555
2023-11-02 RPTX BVF PARTNERS L P/IL 218,979 3.6000 218,979 3.6000 788,324
2023-11-02 RPTX BVF PARTNERS L P/IL 492,251 3.6000 492,251 3.6000 1,772,104
2023-11-02 RPTX BVF PARTNERS L P/IL 72,479 3.6000 72,479 3.6000 260,924
2022-06-13 RPTX BVF PARTNERS L P/IL 74,666 12.7300 74,666 12.7300 950,498
2022-06-13 RPTX BVF PARTNERS L P/IL 68,327 12.7300 68,327 12.7300 869,803
2022-06-13 RPTX BVF PARTNERS L P/IL 6,168 12.7300 6,168 12.7300 78,519
2022-06-06 RPTX BVF PARTNERS L P/IL 3,809 13.2118 3,809 13.2118 50,324
2022-06-06 RPTX BVF PARTNERS L P/IL 3,040 13.2118 3,040 13.2118 40,164
2022-06-06 RPTX BVF PARTNERS L P/IL 20 13.2118 20 13.2118 264
2022-06-03 RPTX BVF PARTNERS L P/IL 353,344 12.2860 353,344 12.2860 4,341,184
2022-06-03 RPTX BVF PARTNERS L P/IL 258,797 12.2860 258,797 12.2860 3,179,580
2022-06-03 RPTX BVF PARTNERS L P/IL 31,903 12.2860 31,903 12.2860 391,960
2022-06-02 RPTX BVF PARTNERS L P/IL 660,654 11.6824 660,654 11.6824 7,718,024
2022-06-02 RPTX BVF PARTNERS L P/IL 464,235 11.6824 464,235 11.6824 5,423,379
2022-06-02 RPTX BVF PARTNERS L P/IL 61,156 11.6824 61,156 11.6824 714,449
2022-05-18 RPTX BVF PARTNERS L P/IL 224,388 8.5000 224,388 8.5000 1,907,298
2022-05-18 RPTX BVF PARTNERS L P/IL 189,882 8.5000 189,882 8.5000 1,613,997
2022-05-18 RPTX BVF PARTNERS L P/IL 5,730 8.5000 5,730 8.5000 48,705
2022-01-19 RPTX BVF PARTNERS L P/IL 577,798 14.1000 577,798 14.1000 8,146,952
2022-01-19 RPTX BVF PARTNERS L P/IL 412,264 14.1000 412,264 14.1000 5,812,922
2022-01-19 RPTX BVF PARTNERS L P/IL 7,899 14.1000 7,899 14.1000 111,376

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RPTX / Repare Therapeutics Inc. Insider Trades
Insider Sales RPTX / Repare Therapeutics Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RPTX / Repare Therapeutics Inc. Insider Trades
Insider Purchases SNDX / Syndax Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insider Sales SNDX / Syndax Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNDX / Syndax Pharmaceuticals, Inc. Insider Trades
Insider Purchases VSTM / Verastem, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VSTM / Verastem, Inc. Insider Trades
Insider Sales VSTM / Verastem, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VSTM / Verastem, Inc. Insider Trades
Insider Purchases XENE / Xenon Pharmaceuticals Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2017-08-15 XENE BVF PARTNERS L P/IL 11,429 2.4122 11,429 2.4122 27,569 359 12.1 110,722 401.62
2017-08-15 XENE BVF PARTNERS L P/IL 7,429 2.4122 7,429 2.4122 17,920
2017-08-14 XENE BVF PARTNERS L P/IL 28,007 2.7036 28,007 2.7036 75,720
2017-08-14 XENE BVF PARTNERS L P/IL 13,337 2.7036 13,337 2.7036 36,058
2017-06-27 XENE BVF PARTNERS L P/IL 46,795 4.0000 46,795 4.0000 187,180
2017-06-27 XENE BVF PARTNERS L P/IL 30,170 4.0000 30,170 4.0000 120,680
2017-06-27 XENE BVF PARTNERS L P/IL 8,496 4.0000 8,496 4.0000 33,984
2017-06-27 XENE BVF PARTNERS L P/IL 46,795 3.0361 46,795 3.0361 142,074
2017-06-27 XENE BVF PARTNERS L P/IL 30,170 3.0361 30,170 3.0361 91,599
2017-06-27 XENE BVF PARTNERS L P/IL 8,496 3.0361 8,496 3.0361 25,795
2017-06-19 XENE BVF PARTNERS L P/IL 1,967 3.8500 1,967 3.8500 7,573
2017-06-19 XENE BVF PARTNERS L P/IL 1,271 3.8500 1,271 3.8500 4,893
2017-06-19 XENE BVF PARTNERS L P/IL 357 3.8500 357 3.8500 1,374
2017-06-16 XENE BVF PARTNERS L P/IL 6,097 3.8500 6,097 3.8500 23,473
2017-06-16 XENE BVF PARTNERS L P/IL 3,873 3.8500 3,873 3.8500 14,911
2017-06-16 XENE BVF PARTNERS L P/IL 1,064 3.8500 1,064 3.8500 4,096
2017-06-15 XENE BVF PARTNERS L P/IL 6,774 3.8370 6,774 3.8370 25,992
2017-06-15 XENE BVF PARTNERS L P/IL 3,845 3.8370 3,845 3.8370 14,753
2017-06-15 XENE BVF PARTNERS L P/IL 1,160 3.8370 1,160 3.8370 4,451
2017-06-07 XENE BVF PARTNERS L P/IL 113,446 3.8512 113,446 3.8512 436,903
2017-06-07 XENE BVF PARTNERS L P/IL 73,749 3.8512 73,749 3.8512 284,022
2017-06-07 XENE BVF PARTNERS L P/IL 20,594 3.8512 20,594 3.8512 79,312
2017-06-06 XENE BVF PARTNERS L P/IL 96,736 3.7500 96,736 3.7500 362,760
2017-06-06 XENE BVF PARTNERS L P/IL 53,260 3.7500 53,260 3.7500 199,725
2017-06-06 XENE BVF PARTNERS L P/IL 913 3.7500 913 3.7500 3,424

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XENE / Xenon Pharmaceuticals Inc. Insider Trades
Insider Sales XENE / Xenon Pharmaceuticals Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XENE / Xenon Pharmaceuticals Inc. Insider Trades
Insider Purchases XOMAO / XOMA Royalty Corporation - Preferred Stock - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CALA / Calithera Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2023-01-06 XOMA BVF PARTNERS L P/IL 1,676 21.9817 1,676 21.9817 36,841 14 23.1200 1,908 5.18
2023-01-06 XOMA BVF PARTNERS L P/IL 1,573 21.9817 1,573 21.9817 34,577
2023-01-05 XOMA BVF PARTNERS L P/IL 3,330 18.3852 3,330 18.3852 61,223
2023-01-05 XOMA BVF PARTNERS L P/IL 15,670 18.3852 15,670 18.3852 288,096
2022-09-27 XOMA BVF PARTNERS L P/IL 1,004 16.8902 1,004 16.8902 16,958
2022-09-27 XOMA BVF PARTNERS L P/IL 678 16.8902 678 16.8902 11,452
2022-09-26 XOMA BVF PARTNERS L P/IL 3,339 16.8317 3,339 16.8317 56,201
2022-09-26 XOMA BVF PARTNERS L P/IL 3,021 16.8317 3,021 16.8317 50,849
2022-09-23 XOMA BVF PARTNERS L P/IL 6,715 16.4970 6,715 16.4970 110,777
2022-09-23 XOMA BVF PARTNERS L P/IL 9,885 16.4970 9,885 16.4970 163,073
2022-09-16 XOMA BVF PARTNERS L P/IL 10,897 17.8873 10,897 17.8873 194,918
2022-09-16 XOMA BVF PARTNERS L P/IL 13,396 17.8873 13,396 17.8873 239,618
2022-09-15 XOMA BVF PARTNERS L P/IL 5,575 17.9620 5,575 17.9620 100,138
2022-09-14 XOMA BVF PARTNERS L P/IL 26,441 17.2476 26,441 17.2476 456,044
2020-09-23 XOMA BVF PARTNERS L P/IL 9,888 18.1998 9,888 18.1998 179,960
2020-09-23 XOMA BVF PARTNERS L P/IL 7,201 18.1998 7,201 18.1998 131,057
2020-09-22 XOMA BVF PARTNERS L P/IL 6,960 18.4457 6,960 18.4457 128,382
2020-09-22 XOMA BVF PARTNERS L P/IL 4,991 18.4457 4,991 18.4457 92,062
2020-09-21 XOMA BVF PARTNERS L P/IL 12,259 18.3851 12,259 18.3851 225,383
2020-09-21 XOMA BVF PARTNERS L P/IL 10,069 18.3851 10,069 18.3851 185,120
2020-09-04 XOMA BVF PARTNERS L P/IL 3,907 18.7706 3,907 18.7706 73,337
2020-09-04 XOMA BVF PARTNERS L P/IL 3,830 18.7706 3,830 18.7706 71,891
2020-09-01 XOMA BVF PARTNERS L P/IL 9,900 18.8661 9,900 18.8661 186,774
2020-09-01 XOMA BVF PARTNERS L P/IL 7,672 18.8661 7,672 18.8661 144,741
2020-08-31 XOMA BVF PARTNERS L P/IL 9,143 18.4806 9,143 18.4806 168,968
2020-08-31 XOMA BVF PARTNERS L P/IL 6,862 18.4806 6,862 18.4806 126,814
2020-08-28 XOMA BVF PARTNERS L P/IL 1,122 19.1719 1,122 19.1719 21,511
2020-08-28 XOMA BVF PARTNERS L P/IL 922 19.1719 922 19.1719 17,676
2020-08-25 XOMA BVF PARTNERS L P/IL 3,443 19.7450 3,443 19.7450 67,982
2020-08-25 XOMA BVF PARTNERS L P/IL 2,244 19.7450 2,244 19.7450 44,308
2020-08-24 XOMA BVF PARTNERS L P/IL 6,504 19.3093 6,504 19.3093 125,588
2020-08-24 XOMA BVF PARTNERS L P/IL 5,179 19.3093 5,179 19.3093 100,003
2020-08-21 XOMA BVF PARTNERS L P/IL 9,198 19.3216 9,198 19.3216 177,720
2020-08-21 XOMA BVF PARTNERS L P/IL 1,607 19.3216 1,607 19.3216 31,050
2020-08-20 XOMA BVF PARTNERS L P/IL 1,772 19.1200 1,772 19.1200 33,881
2020-08-19 XOMA BVF PARTNERS L P/IL 3,496 19.7016 3,496 19.7016 68,877
2020-08-18 XOMA BVF PARTNERS L P/IL 895 19.2694 895 19.2694 17,246
2020-08-14 XOMA BVF PARTNERS L P/IL 21,922 18.6940 21,922 18.6940 409,810
2020-08-13 XOMA BVF PARTNERS L P/IL 1,050 17.8032 1,050 17.8032 18,693
2020-08-12 XOMA BVF PARTNERS L P/IL 4,050 17.3415 4,050 17.3415 70,233
2020-03-25 XOMA BVF PARTNERS L P/IL 8,264 17.1986 8,264 17.1986 142,129
2020-03-18 XOMA BVF PARTNERS L P/IL 4,439 14.5246 4,439 14.5246 64,475
2020-03-17 XOMA BVF PARTNERS L P/IL 8,113 15.7337 8,113 15.7337 127,648
2020-03-16 XOMA BVF PARTNERS L P/IL 10,164 15.7336 10,164 15.7336 159,916
2020-03-13 XOMA BVF PARTNERS L P/IL 100,000 18.3409 100,000 18.3409 1,834,090
2019-12-19 XOMA BVF PARTNERS L P/IL 207,234 22.0000 207,234 22.0000 4,559,148
2019-12-19 XOMA BVF PARTNERS L P/IL 165,961 22.0000 165,961 22.0000 3,651,142
2019-05-14 XOMA BVF PARTNERS L P/IL 13,816 14.7412 13,816 14.7412 203,664
2019-05-13 XOMA BVF PARTNERS L P/IL 3,797 14.3604 3,797 14.3604 54,526
2019-05-10 XOMA BVF PARTNERS L P/IL 10,300 14.5667 10,300 14.5667 150,037
2018-12-17 XOMA BVF PARTNERS L P/IL 25,000 14.1917 25,000 14.1917 354,792
2018-12-13 XOMA BVF PARTNERS L P/IL 24,253 14.4116 24,253 14.4116 349,525
2018-12-12 XOMA BVF PARTNERS L P/IL 2,810 14.7500 2,810 14.7500 41,448
2018-12-11 XOMA BVF PARTNERS L P/IL 9,400 14.4968 9,400 14.4968 136,270
2018-12-10 XOMA BVF PARTNERS L P/IL 18,081 14.5441 18,081 14.5441 262,972
2018-12-07 XOMA BVF PARTNERS L P/IL 32,015 14.7674 32,015 14.7674 472,778
2018-12-06 XOMA BVF PARTNERS L P/IL 10,927 14.7980 10,927 14.7980 161,698
2018-12-04 XOMA BVF PARTNERS L P/IL 4,171 14.9880 4,171 14.9880 62,515
2018-12-03 XOMA BVF PARTNERS L P/IL 806 14.9000 806 14.9000 12,009
2018-11-30 XOMA BVF PARTNERS L P/IL 4,823 14.8486 4,823 14.8486 71,615
2018-11-29 XOMA BVF PARTNERS L P/IL 10,016 14.9304 10,016 14.9304 149,543
2018-11-28 XOMA BVF PARTNERS L P/IL 8,288 15.1136 8,288 15.1136 125,262
2018-11-27 XOMA BVF PARTNERS L P/IL 11,396 15.2404 11,396 15.2404 173,680
2018-11-21 XOMA BVF PARTNERS L P/IL 25,000 14.9957 25,000 14.9957 374,892
2018-11-20 XOMA BVF PARTNERS L P/IL 37,482 13.6786 37,482 13.6786 512,701
2018-11-19 XOMA BVF PARTNERS L P/IL 9,771 13.9253 9,771 13.9253 136,064
2018-11-16 XOMA BVF PARTNERS L P/IL 10,849 13.8249 10,849 13.8249 149,986
2018-11-15 XOMA BVF PARTNERS L P/IL 21,141 13.3088 21,141 13.3088 281,361

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XOMAO / XOMA Royalty Corporation - Preferred Stock Insider Trades
Insider Sales XOMAO / XOMA Royalty Corporation - Preferred Stock - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CALA / Calithera Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2025-05-16 XOMA BVF PARTNERS L P/IL 127,407 27.1000 127,407 27.1000 3,452,730 28 23.8500 -414,072 -11.99
2025-05-16 XOMA BVF PARTNERS L P/IL 265,316 27.1000 265,316 27.1000 7,190,064
2025-01-24 XOMA BVF PARTNERS L P/IL 339,679 26.1000 339,679 26.1000 8,865,622
2025-01-24 XOMA BVF PARTNERS L P/IL 85,776 26.1000 85,776 26.1000 2,238,754
2025-01-24 XOMA BVF PARTNERS L P/IL 75,287 26.1000 75,287 26.1000 1,964,991
2025-01-24 XOMA BVF PARTNERS L P/IL 149,975 26.1000 149,975 26.1000 3,914,348
2021-03-31 XOMA BVF PARTNERS L P/IL 279,740 38.3600 279,740 38.3600 10,730,826
2021-03-31 XOMA BVF PARTNERS L P/IL 205,807 38.3600 205,807 38.3600 7,894,757
2021-03-31 XOMA BVF PARTNERS L P/IL 84,250 38.3600 84,250 38.3600 3,231,830
2021-03-31 XOMA BVF PARTNERS L P/IL 81,903 38.3600 81,903 38.3600 3,141,799

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

XOMAO / XOMA Royalty Corporation - Preferred Stock Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark N Lampert as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock 		S - Sale -11 560,797 0.00 1.88 -21 1,053,121
2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock 		S - Sale -66 4,726,743 0.00 1.88 -124 8,876,351
2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock 		S - Sale -79 6,194,145 0.00 1.88 -148 11,631,985
2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock 		X - Other 203,336 560,808 56.88 0.00 20 56
2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock 		X - Other 1,235,030 4,726,809 35.37 0.00 124 473
2025-08-07 2025-08-05 4 EPIX ESSA Pharma Inc.
Common Stock 		X - Other 1,481,634 6,194,224 31.44 0.00 148 619
2025-07-01 2025-06-30 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 58,780 353,412 19.95 44.00 2,586,320 15,550,128
2025-07-01 2025-06-30 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 115,783 2,219,858 5.50 44.00 5,094,452 97,673,752
2025-07-01 2025-06-30 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 142,604 2,798,795 5.37 44.00 6,274,576 123,146,980
2025-06-17 2025-06-13 4 CBIO GLYCOMIMETICS INC
Common Stock 		J - Other 56,079 62,383 889.58
2025-06-17 2025-06-13 4 CBIO GLYCOMIMETICS INC
Common Stock 		J - Other 556,617 593,740 1,499.39
2025-06-17 2025-06-13 4 CBIO GLYCOMIMETICS INC
Common Stock 		J - Other 657,308 707,116 1,319.68
2025-05-20 2025-05-16 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share 		S - Sale -265,316 1,267,545 -17.31 27.10 -7,190,064 34,350,470
2025-05-20 2025-05-16 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share 		S - Sale -127,407 1,322,758 -8.79 27.10 -3,452,730 35,846,742
2025-05-19 2025-05-15 4 ALLK Allakos Inc.
Common Stock, $0.001 par value 		D - Sale to Issuer -855,211 0 -100.00
2025-05-19 2025-05-15 4 ALLK Allakos Inc.
Common Stock, $0.001 par value 		D - Sale to Issuer -6,777,935 0 -100.00
2025-05-19 2025-05-15 4 ALLK Allakos Inc.
Common Stock, $0.001 par value 		D - Sale to Issuer -8,679,726 0 -100.00
2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share 		S - Sale -149,975 0 -100.00 26.10 -3,914,348
2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share 		S - Sale -75,287 0 -100.00 26.10 -1,964,991
2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share 		S - Sale -85,776 1,532,861 -5.30 26.10 -2,238,754 40,007,672
2025-01-28 2025-01-24 4 XOMA XOMA Royalty Corp
Common Stock, $0.0075 par value per share 		S - Sale -339,679 1,450,165 -18.98 26.10 -8,865,622 37,849,306
2025-01-14 2025-01-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		D - Sale to Issuer -22,740 347,970 -6.13
2025-01-14 2025-01-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		D - Sale to Issuer -161,810 2,003,966 -7.47
2025-01-14 2025-01-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		D - Sale to Issuer -235,450 2,655,977 -8.14
2024-12-17 2024-12-13 4 PVLA PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value 		J - Other 29,648 38,961 318.35
2024-12-17 2024-12-13 4 PVLA PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value 		J - Other 174,958 282,223 163.11
2024-12-17 2024-12-13 4 PVLA PALVELLA THERAPEUTICS, INC.
Common Stock, $0.001 par value 		J - Other 234,323 371,916 170.30
2024-12-04 2024-12-04 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		D - Sale to Issuer -153,441 370,710 -29.27
2024-12-04 2024-12-04 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		D - Sale to Issuer -1,418,736 2,165,776 -39.58
2024-12-04 2024-12-04 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		D - Sale to Issuer -1,797,527 2,891,427 -38.34
2024-11-13 2024-11-08 4 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 		J - Other -240,000 87,911 -73.19
2024-11-13 2024-11-08 4 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 		J - Other -2,378,000 662,970 -78.20
2024-11-13 2024-11-08 4 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 		J - Other -3,062,000 830,237 -78.67
2024-10-31 2024-10-29 4 THRD Third Harmonic Bio, Inc.
Common Stock 		S - Sale -64,617 176,692 -26.78 14.30 -924,023 2,526,696
2024-10-31 2024-10-29 4 THRD Third Harmonic Bio, Inc.
Common Stock 		S - Sale -396,963 1,367,257 -22.50 14.30 -5,676,571 19,551,775
2024-10-31 2024-10-29 4 THRD Third Harmonic Bio, Inc.
Common Stock 		S - Sale -538,420 1,794,218 -23.08 14.30 -7,699,406 25,657,317
2024-10-08 2024-10-04 4 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 		S - Sale -132,549 1,287,768 -9.33 50.00 -6,627,662 64,390,460
2024-10-08 2024-10-04 4 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 		S - Sale -836,862 8,168,838 -9.29 50.00 -41,844,439 408,454,970
2024-10-08 2024-10-04 4 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 		S - Sale -1,030,589 10,235,089 -9.15 50.00 -51,531,099 511,770,826
2024-08-01 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 		3,892,237
2024-08-01 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 		3,040,970
2024-08-01 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock, $0.0001 par value 		327,911
2024-05-13 2024-05-09 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		P - Purchase 75,431 220,460 52.01
2024-05-13 2024-05-09 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		P - Purchase 821,121 2,633,679 45.30
2024-05-13 2024-05-09 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		P - Purchase 1,031,385 3,361,803 44.26
2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value 		U - Other -341,547 0 -100.00
2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Common Stock, $0.001 par value 		U - Other -185,388 0 -100.00
2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value 		U - Other -2,076,085 0 -100.00
2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Common Stock, $0.001 par value 		U - Other -1,367,838 0 -100.00
2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Non-Voting Common Stock, $0.001 par value 		U - Other -2,870,985 0 -100.00
2024-01-29 2024-01-25 4 RAIN Rain Oncology Inc.
Common Stock, $0.001 par value 		U - Other -1,734,960 0 -100.00
2024-01-26 3 ALLK Allakos Inc.
Common Stock, $0.001 par value 		8,679,726
2024-01-26 3 ALLK Allakos Inc.
Common Stock, $0.001 par value 		6,777,935
2024-01-26 3 ALLK Allakos Inc.
Common Stock, $0.001 par value 		855,211
2023-12-20 2023-12-18 4 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 		S - Sale -896,366 0 -100.00 12.45 -11,159,757
2023-12-20 2023-12-18 4 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 		S - Sale -7,290,667 0 -100.00 12.45 -90,768,804
2023-12-20 2023-12-18 4 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 		S - Sale -8,974,245 0 -100.00 12.45 -111,729,350
2023-11-17 2023-11-16 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 16,143 548,938 3.03 5.38 86,909 2,955,318
2023-11-17 2023-11-16 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 125,909 4,308,573 3.01 5.38 677,856 23,196,064
2023-11-17 2023-11-16 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 153,693 5,309,432 2.98 5.38 827,437 28,584,389
2023-11-17 2023-11-15 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 47,712 532,795 9.84 5.00 238,555 2,663,922
2023-11-17 2023-11-15 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 390,507 4,182,664 10.30 5.00 1,952,496 20,912,902
2023-11-17 2023-11-15 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 493,337 5,155,739 10.58 5.00 2,466,636 25,778,179
2023-11-13 3 ENGN enGene Holdings Inc.
Class A Common Shares 		1,204,412
2023-11-13 3 ENGN enGene Holdings Inc.
Class A Common Shares 		912,776
2023-11-13 3 ENGN enGene Holdings Inc.
Class A Common Shares 		104,257
2023-11-06 3 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 		8,974,245
2023-11-06 3 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 		7,290,667
2023-11-06 3 PNT POINT Biopharma Global Inc.
Common Stock, $0.0001 par value 		896,366
2023-11-06 2023-11-03 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 10,106 294,632 3.55 14.07 142,180 4,145,148
2023-11-06 2023-11-03 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 83,708 2,104,075 4.14 14.07 1,177,679 29,602,021
2023-11-06 2023-11-03 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 103,885 2,656,191 4.07 14.07 1,461,548 37,369,686
2023-11-06 2023-11-02 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 26,772 284,526 10.39 11.64 311,744 3,313,135
2023-11-06 2023-11-02 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 132,016 2,020,367 6.99 11.64 1,537,247 23,525,961
2023-11-06 2023-11-02 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 57,618 2,552,306 2.31 11.64 670,927 29,720,072
2023-11-03 2023-11-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 72,479 485,083 17.57 3.60 260,924 1,746,299
2023-11-03 2023-11-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 492,251 3,792,157 14.92 3.60 1,772,104 13,651,765
2023-11-03 2023-11-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 218,979 4,662,402 4.93 3.60 788,324 16,784,647
2023-09-14 2023-09-14 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		J - Other 99,556 99,556
2023-09-14 2023-09-12 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 52,801 524,151 11.20 9.84 519,562 5,157,646
2023-09-14 2023-09-12 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 677,853 3,584,512 23.32 9.84 6,670,074 35,271,598
2023-09-14 2023-09-12 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 775,278 4,688,954 19.81 9.84 7,628,736 46,139,307
2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		U - Other -43,139 0 -100.00 9.10 -392,565
2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		U - Other -1,526,147 0 -100.00 9.10 -13,887,938
2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		U - Other -702,505 0 -100.00 9.10 -6,392,796
2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		U - Other -2,595,239 0 -100.00 9.10 -23,616,675
2023-06-28 2023-06-26 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		U - Other -3,989,130 0 -100.00 9.10 -36,301,083
2023-05-22 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		11,007,420
2023-05-22 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		8,581,171
2023-05-22 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		744,966
2023-05-12 2023-05-10 4 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		J - Other -462,605 0 -100.00
2023-05-12 2023-05-10 4 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		J - Other -2,929,660 0 -100.00
2023-05-12 2023-05-10 4 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		J - Other -4,018,253 0 -100.00
2023-05-09 2023-05-05 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		P - Purchase 86,341 145,029 147.12
2023-05-09 2023-05-05 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		P - Purchase 837,146 1,812,558 85.82
2023-05-09 2023-05-05 4 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		P - Purchase 1,055,445 2,330,418 82.78
2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		4,018,253
2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		2,801,529
2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		2,929,660
2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		2,130,657
2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		462,605
2023-02-13 3 GPCR Structure Therapeutics Inc.
Ordinary Shares, $0.0001 par value per share 		241,755
2023-01-19 2023-01-19 4 CGEM Cullinan Oncology, Inc.
Common Stock 		J - Other -300,000 64,161 -82.38
2023-01-19 2023-01-19 4 CGEM Cullinan Oncology, Inc.
Common Stock 		J - Other -2,600,000 392,808 -86.87
2023-01-19 2023-01-19 4 CGEM Cullinan Oncology, Inc.
Common Stock 		J - Other -3,500,000 558,854 -86.23
2023-01-13 2023-01-12 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 15,912 1,888,351 0.85 31.24 497,132 58,996,995
2023-01-13 2023-01-12 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 2,985 2,494,688 0.12 31.24 93,259 77,940,539
2023-01-13 2023-01-11 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 11,149 1,872,439 0.60 29.89 333,209 55,961,397
2023-01-13 2023-01-11 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 10,961 2,491,703 0.44 29.89 327,590 74,469,278
2023-01-09 2023-01-06 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 1,573 1,618,637 0.10 21.98 34,577 35,580,393
2023-01-09 2023-01-06 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 1,676 1,789,844 0.09 21.98 36,841 39,343,814
2023-01-09 2023-01-05 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 15,670 1,617,064 0.98 18.39 288,096 29,730,045
2023-01-09 2023-01-05 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,330 1,788,168 0.19 18.39 61,223 32,875,826
2022-12-22 2022-12-20 4 THRD Third Harmonic Bio, Inc.
Common Stock 		P - Purchase 9,597 241,309 4.14 4.11 39,430 991,442
2022-12-22 2022-12-20 4 THRD Third Harmonic Bio, Inc.
Common Stock 		P - Purchase 87,831 1,764,220 5.24 4.11 360,862 7,248,474
2022-12-22 2022-12-20 4 THRD Third Harmonic Bio, Inc.
Common Stock 		P - Purchase 116,635 2,332,638 5.26 4.11 479,207 9,583,876
2022-12-22 3 THRD Third Harmonic Bio, Inc.
Common Stock 		2,216,003
2022-12-22 3 THRD Third Harmonic Bio, Inc.
Common Stock 		1,676,389
2022-12-22 3 THRD Third Harmonic Bio, Inc.
Common Stock 		231,712
2022-11-10 2022-11-08 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		P - Purchase 54,857 341,547 19.13 5.83 319,816 1,991,219
2022-11-10 2022-11-08 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		P - Purchase 685,330 2,076,085 49.28 5.83 3,995,474 12,103,576
2022-11-10 2022-11-08 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		P - Purchase 970,171 2,870,985 51.04 5.83 5,656,097 16,737,843
2022-09-27 2022-09-27 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 678 1,601,394 0.04 16.89 11,452 27,047,865
2022-09-27 2022-09-27 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 1,004 1,784,838 0.06 16.89 16,958 30,146,271
2022-09-27 2022-09-26 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,021 1,600,716 0.19 16.83 50,849 26,942,771
2022-09-27 2022-09-26 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,339 1,783,834 0.19 16.83 56,201 30,024,959
2022-09-27 2022-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 9,885 1,597,695 0.62 16.50 163,073 26,357,174
2022-09-27 2022-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 6,715 1,780,495 0.38 16.50 110,777 29,372,826
2022-09-16 2022-09-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 13,396 1,773,780 0.76 17.89 239,618 31,728,135
2022-09-16 2022-09-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 10,897 1,587,810 0.69 17.89 194,918 28,401,634
2022-09-16 2022-09-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 5,575 1,576,913 0.35 17.96 100,138 28,324,511
2022-09-16 2022-09-14 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 26,441 1,571,338 1.71 17.25 456,044 27,101,809
2022-08-23 2022-08-22 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 27,117 257,754 11.76 26.00 705,042 6,701,604
2022-08-23 2022-08-22 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 233,362 1,861,290 14.33 26.00 6,067,412 48,393,540
2022-08-23 2022-08-22 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 285,046 2,480,742 12.98 26.00 7,411,196 64,499,292
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		C - Conversion 1,519,999 1,526,147 24,723.47
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		S - Sale -1,289,434 6,148 -99.53 6.12 -7,891,336 37,626
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		C - Conversion 682,666 702,505 3,441.03
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		S - Sale -469,040 19,839 -95.94 6.12 -2,870,525 121,415
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		C - Conversion 2,426,666 2,595,239 1,439.53
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		S - Sale -2,890,723 168,573 -94.49 6.12 -17,691,225 1,031,667
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		C - Conversion 3,754,000 3,989,130 1,596.56
2022-08-11 2022-08-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		S - Sale -3,850,803 235,130 -94.25 6.12 -23,566,914 1,438,996
2022-07-21 3 EPIX ESSA Pharma Inc.
Common Stock 		4,712,590
2022-07-21 3 EPIX ESSA Pharma Inc.
Common Stock 		3,491,779
2022-07-21 3 EPIX ESSA Pharma Inc.
Common Stock 		357,472
2022-06-27 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock 		2,132,411
2022-06-27 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock 		1,570,857
2022-06-27 3 FDMT 4D Molecular Therapeutics, Inc.
Common Stock 		209,716
2022-06-15 2022-06-13 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 6,168 412,604 1.52 12.73 78,519 5,252,449
2022-06-15 2022-06-13 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 68,327 3,299,906 2.11 12.73 869,803 42,007,803
2022-06-15 2022-06-13 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 74,666 4,443,423 1.71 12.73 950,498 56,564,775
2022-06-14 2022-06-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 41,417 2,906,659 1.45 4.03 167,097 11,726,916
2022-06-14 2022-06-10 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 158,583 3,913,676 4.22 4.03 639,803 15,789,726
2022-06-06 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 20 406,436 0.00 13.21 264 5,369,751
2022-06-06 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 3,040 3,231,579 0.09 13.21 40,164 42,694,975
2022-06-06 2022-06-06 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 3,809 4,368,757 0.09 13.21 50,324 57,719,144
2022-06-06 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 31,903 406,416 8.52 12.29 391,960 4,993,227
2022-06-06 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 258,797 3,228,539 8.71 12.29 3,179,580 39,665,830
2022-06-06 2022-06-03 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 353,344 4,364,948 8.81 12.29 4,341,184 53,627,751
2022-06-06 2022-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 61,156 374,513 19.52 11.68 714,449 4,375,211
2022-06-06 2022-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 464,235 2,969,742 18.53 11.68 5,423,379 34,693,714
2022-06-06 2022-06-02 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 660,654 4,011,604 19.72 11.68 7,718,024 46,865,163
2022-06-03 2022-06-01 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 44,746 364,161 14.01 11.00 492,179 4,005,553
2022-06-03 2022-06-01 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 301,009 2,992,808 11.18 11.00 3,310,918 32,919,092
2022-06-03 2022-06-01 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 405,641 4,058,854 11.10 11.00 4,461,808 44,644,959
2022-05-31 2022-05-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 3,223 230,637 1.42 14.78 47,645 3,409,461
2022-05-31 2022-05-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 26,353 1,627,928 1.65 14.78 389,571 24,065,334
2022-05-31 2022-05-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 35,793 2,195,696 1.66 14.78 529,121 32,458,535
2022-05-31 2022-05-26 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 10,642 227,414 4.91 14.21 151,229 3,231,689
2022-05-31 2022-05-26 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 90,372 1,601,575 5.98 14.21 1,284,240 22,759,342
2022-05-31 2022-05-26 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 123,043 2,159,903 6.04 14.21 1,748,515 30,693,518
2022-05-24 2022-05-20 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 37 216,772 0.02 14.00 518 3,034,678
2022-05-24 2022-05-20 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 4,180 1,511,203 0.28 14.00 58,517 21,155,935
2022-05-24 2022-05-20 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 5,883 2,036,860 0.29 14.00 82,358 28,514,818
2022-05-20 2022-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 5,730 313,357 1.86 8.50 48,705 2,663,534
2022-05-20 2022-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 189,882 2,505,507 8.20 8.50 1,613,997 21,296,810
2022-05-20 2022-05-18 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 224,388 3,350,950 7.18 8.50 1,907,298 28,483,075
2022-05-20 2022-05-18 4 XOMA XOMA Corp
Non-Qualified Stock Option (right to buy) 		A - Award 8,996 8,996
2022-05-16 2022-05-13 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 17,744 319,415 5.88 9.14 162,091 2,917,856
2022-05-16 2022-05-13 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 38,558 2,691,799 1.45 9.14 352,227 24,589,584
2022-05-16 2022-05-13 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 53,598 3,653,213 1.49 9.14 489,618 33,372,101
2022-05-16 2022-05-12 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 457,001 2,653,241 20.81 9.06 4,140,429 24,038,363
2022-05-16 2022-05-12 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 542,999 3,599,615 17.76 9.06 4,919,571 32,612,512
2022-05-09 2022-05-06 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 4,131 216,735 1.94 19.26 79,542 4,173,232
2022-05-09 2022-05-06 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 40,659 1,507,023 2.77 19.26 782,889 29,017,728
2022-05-09 2022-05-06 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 55,210 2,030,977 2.79 19.26 1,063,069 39,106,462
2022-05-09 2022-05-05 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 4,066 212,604 1.95 19.60 79,690 4,166,847
2022-05-09 2022-05-05 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 70,439 1,466,364 5.05 19.60 1,380,541 28,739,415
2022-05-09 2022-05-05 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 75,495 1,975,767 3.97 19.60 1,479,634 38,723,255
2022-04-15 3 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 		11,265,678
2022-04-15 3 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 		9,005,699
2022-04-15 3 MLTX MoonLake Immunotherapeutics
Class A Ordinary Shares, $0.0001 par value 		1,420,317
2022-04-05 2022-04-01 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 9,402 2,196,240 0.43 10.75 101,071 23,609,360
2022-04-05 2022-04-01 4 CGEM Cullinan Oncology, Inc.
Common Stock 		P - Purchase 266,598 3,056,616 9.56 10.75 2,865,902 32,858,316
2022-03-11 2022-03-09 4 CTIC CTI BIOPHARMA CORP
Stock Option (Right to Buy) 		A - Award 80,000 80,000
2022-02-07 3 VSTM Verastem, Inc.
Common Stock 		10,753,294
2022-02-07 3 VSTM Verastem, Inc.
Common Stock 		7,883,287
2022-02-07 3 VSTM Verastem, Inc.
Common Stock 		994,353
2022-01-31 2022-01-31 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 14,323 1,395,925 1.04 40.70 582,946 56,814,148
2022-01-31 2022-01-31 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 20,085 1,900,272 1.07 40.70 817,460 77,341,070
2022-01-31 2022-01-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 37,859 1,381,602 2.82 38.33 1,451,207 52,959,430
2022-01-31 2022-01-27 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 58,042 1,880,187 3.19 38.33 2,224,860 72,071,140
2022-01-31 3 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		1,274,973
2022-01-31 3 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		975,412
2022-01-31 3 ELDN Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		58,688
2022-01-26 2022-01-24 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 114,726 1,343,743 9.33 37.76 4,332,455 50,744,439
2022-01-26 2022-01-24 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 158,041 1,822,145 9.50 37.76 5,968,181 68,810,573
2022-01-21 2022-01-19 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 7,899 307,627 2.64 14.10 111,376 4,337,541
2022-01-21 2022-01-19 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 412,264 2,315,625 21.66 14.10 5,812,922 32,650,312
2022-01-21 2022-01-19 4 RPTX Repare Therapeutics Inc.
Common Shares, no par value 		P - Purchase 577,798 3,126,562 22.67 14.10 8,146,952 44,084,524
2022-01-10 3 CGEM Cullinan Oncology, Inc.
Common Stock 		2,790,018
2022-01-10 3 CGEM Cullinan Oncology, Inc.
Common Stock 		2,186,838
2022-01-10 3 CGEM Cullinan Oncology, Inc.
Common Stock 		301,671
2022-01-10 2022-01-07 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 14,806 185,388 8.68 12.00 177,672 2,224,656
2022-01-10 2022-01-07 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 226,079 1,367,838 19.80 12.00 2,712,948 16,414,056
2022-01-10 2022-01-07 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 255,500 1,734,960 17.27 12.00 3,066,000 20,819,520
2022-01-10 2022-01-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 61,343 1,141,759 5.68 12.00 736,018 13,699,281
2021-12-02 2021-11-30 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 35,268 471,350 8.09 9.39 331,177 4,426,118
2021-12-02 2021-11-30 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 341,977 2,865,242 13.55 9.39 3,211,267 26,905,482
2021-12-02 2021-11-30 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 362,430 3,755,093 10.68 9.39 3,403,326 35,261,450
2021-11-08 3 RPTX Repare Therapeutics Inc.
Common Stock 		2,548,764
2021-11-08 3 RPTX Repare Therapeutics Inc.
Common Stock 		1,903,361
2021-11-08 3 RPTX Repare Therapeutics Inc.
Common Stock 		299,728
2021-10-08 2021-10-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -8,929 232,747 -3.69 27.79 -248,106 6,467,225
2021-10-08 2021-10-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -58,327 1,520,405 -3.69 27.79 -1,620,703 42,246,734
2021-10-08 2021-10-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -80,011 2,085,664 -3.69 27.79 -2,223,226 57,953,303
2021-10-08 2021-10-07 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -69,534 241,676 -22.34 27.53 -1,914,348 6,653,606
2021-10-08 2021-10-07 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -384,914 1,578,732 -19.60 27.53 -10,597,106 43,464,229
2021-10-08 2021-10-07 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -530,999 2,165,675 -19.69 27.53 -14,618,987 59,623,415
2021-09-23 2021-09-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 590 170,582 0.35 13.94 8,226 2,378,357
2021-09-23 2021-09-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 4,102 1,080,416 0.38 13.94 57,193 15,063,808
2021-09-23 2021-09-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 6,341 1,479,460 0.43 13.94 88,410 20,627,519
2021-09-15 2021-09-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 20,512 169,992 13.72 16.49 338,243 2,803,168
2021-09-15 2021-09-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 158,511 1,076,314 17.27 16.49 2,613,846 17,748,418
2021-09-15 2021-09-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 213,246 1,473,119 16.93 16.49 3,516,427 24,291,732
2021-07-07 2021-07-02 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -150,805 311,210 -32.64 20.75 -3,129,204 6,457,608
2021-07-07 2021-07-02 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -928,739 1,963,646 -32.11 20.75 -19,271,334 40,745,654
2021-07-07 2021-07-02 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		S - Sale -1,106,478 2,696,674 -29.09 20.75 -22,959,418 55,955,986
2021-07-06 2021-07-01 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 27,458 208,538 15.16 47.00 1,290,526 9,801,286
2021-07-06 2021-07-01 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 211,711 1,229,017 20.81 47.00 9,950,417 57,763,799
2021-07-06 2021-07-01 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		P - Purchase 304,997 1,664,104 22.44 47.00 14,334,859 78,212,888
2021-07-06 2021-07-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 16,980 149,480 12.82 15.25 258,945 2,279,570
2021-07-06 2021-07-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 106,627 917,803 13.14 15.25 1,626,062 13,996,496
2021-07-06 2021-07-06 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 146,116 1,259,873 13.12 15.25 2,228,269 19,213,063
2021-07-06 2021-07-01 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 20,018 132,500 17.80 15.65 313,282 2,073,625
2021-07-06 2021-07-01 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 124,804 811,176 18.18 15.65 1,953,183 12,694,904
2021-07-06 2021-07-01 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 172,457 1,113,757 18.32 15.65 2,698,952 17,430,297
2021-06-21 2021-06-16 4 KYMR Kymera Therapeutics, Inc.
Stock Option (Right to Buy) 		A - Award 20,063 20,063
2021-05-26 2021-03-31 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		J - Other 99,556 99,556
2021-05-25 2021-05-24 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 129 112,482 0.11 15.90 2,050 1,787,924
2021-05-25 2021-05-24 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 513 686,372 0.07 15.90 8,154 10,910,020
2021-05-25 2021-05-24 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 719 941,300 0.08 15.90 11,429 14,962,152
2021-05-25 2021-05-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 7,592 112,353 7.25 15.94 121,032 1,791,132
2021-05-25 2021-05-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 48,152 685,859 7.55 15.94 767,639 10,933,964
2021-05-25 2021-05-21 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 66,242 940,581 7.58 15.94 1,056,030 14,994,742
2021-05-21 2021-05-19 4 XOMA XOMA Corp
Non-Qualified Stock Option (right to buy) 		A - Award 5,101 5,101
2021-05-20 2021-05-19 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 1,115 104,761 1.08 15.88 17,711 1,664,055
2021-05-20 2021-05-19 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 6,962 637,707 1.10 15.88 110,586 10,129,529
2021-05-20 2021-05-19 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 9,191 874,339 1.06 15.88 145,993 13,888,263
2021-05-20 2021-05-18 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 11,946 103,646 13.03 16.65 198,901 1,725,706
2021-05-20 2021-05-18 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 75,640 630,745 13.63 16.65 1,259,406 10,501,904
2021-05-20 2021-05-18 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 103,611 865,148 13.61 16.65 1,725,123 14,404,714
2021-05-17 2021-04-26 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 1,747 88,226 2.02 14.90 26,032 1,314,647
2021-05-17 2021-04-26 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 10,876 532,384 2.09 14.90 162,062 7,933,001
2021-05-17 2021-04-26 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 14,790 729,732 2.07 14.90 220,384 10,873,664
2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 6,141 86,479 7.64 15.93 97,817 1,377,481
2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 62,948 80,338 361.98 17.00 1,070,116 1,365,746
2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 38,858 521,508 8.05 15.93 618,950 8,306,840
2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 398,300 482,650 472.20 17.00 6,771,100 8,205,050
2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 53,303 714,942 8.06 15.93 849,037 11,387,954
2021-05-17 2021-04-23 4/A RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 546,346 661,639 473.88 17.00 9,287,882 11,247,863
2021-05-17 2021-05-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 3,474 91,700 3.94 14.26 49,544 1,307,780
2021-05-17 2021-05-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 22,721 555,105 4.27 14.26 324,036 7,916,630
2021-05-17 2021-05-13 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		P - Purchase 31,805 761,537 4.36 14.26 453,587 10,860,660
2021-04-27 2021-04-26 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 1,747 88,226 2.02 14.90 26,032 1,314,647
2021-04-27 2021-04-26 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 10,876 532,384 2.09 14.90 162,062 7,933,001
2021-04-27 2021-04-26 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 14,790 729,732 2.07 14.90 220,384 10,873,664
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series B Convertible Preferred Stock 		C - Conversion -134,515 0 -100.00
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock 		C - Conversion -152,176 0 -100.00
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock 		C - Conversion -17,390 152,176 -10.26
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series B Convertible Preferred Stock 		C - Conversion -837,397 0 -100.00
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock 		C - Conversion -553,359 0 -100.00
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock 		C - Conversion -84,350 553,359 -13.23
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series B Convertible Preferred Stock 		C - Conversion -1,068,554 0 -100.00
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock 		C - Conversion -832,261 0 -100.00
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Series A Convertible Preferred Stock 		C - Conversion -115,293 832,261 -12.17
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		C - Conversion 134,515 286,691 88.39
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		C - Conversion 152,176 152,176
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 6,141 86,479 7.64 15.93 97,817 1,377,481
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 62,948 80,338 361.98 17.00 1,070,116 1,365,746
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		C - Conversion 17,390 17,390
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		C - Conversion 837,397 1,390,756 151.33
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		C - Conversion 553,359 553,359
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 38,858 521,508 8.05 15.93 618,950 8,306,840
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 398,300 482,650 472.20 17.00 6,771,100 8,205,050
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		C - Conversion 84,350 84,350
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		C - Conversion 1,068,554 1,900,815 128.39
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Non-Voting Common Stock, $0.001 par value 		C - Conversion 832,261 832,261
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 53,303 714,942 8.06 15.93 849,037 11,387,954
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		A - Award 546,346 661,639 473.88 17.00 9,287,882 11,247,863
2021-04-27 2021-04-23 4 RAIN Rain Therapeutics Inc.
Common Stock, $0.001 par value 		C - Conversion 115,293 115,293
2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock 		P - Purchase 17 17 25,000.00 425,000 425,000
2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock 		P - Purchase 239 239 25,000.00 5,975,000 5,975,000
2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Series X1 Convertible Preferred Stock 		P - Purchase 344 344 25,000.00 8,600,000 8,600,000
2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		P - Purchase 5,171 488,879 1.07 2.50 12,928 1,222,198
2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		P - Purchase 950,016 3,059,296 45.04 2.50 2,375,040 7,648,240
2021-04-05 2021-04-01 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		P - Purchase 1,044,813 4,085,933 34.36 2.50 2,612,032 10,214,832
2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		S - Sale -81,903 149,975 -35.32 38.36 -3,141,799 5,753,041
2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		S - Sale -84,250 75,287 -52.81 38.36 -3,231,830 2,888,009
2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		S - Sale -205,807 1,544,897 -11.76 38.36 -7,894,757 59,262,249
2021-04-02 2021-03-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		S - Sale -279,740 1,760,384 -13.71 38.36 -10,730,826 67,528,330
2021-04-01 2021-03-30 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 26,894 462,015 6.18 19.75 531,156 9,124,796
2021-04-01 2021-03-30 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 108,106 2,892,385 3.88 19.75 2,135,094 57,124,604
2021-04-01 2021-03-30 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 165,000 3,803,152 4.54 19.75 3,258,750 75,112,252
2021-03-24 2021-03-22 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 7,744 435,121 1.81 22.75 176,176 9,899,003
2021-03-24 2021-03-22 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 71,756 3,638,152 2.01 22.75 1,632,449 82,767,958
2021-03-18 2021-03-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 1,171 427,377 0.27 23.00 26,933 9,829,500
2021-03-18 2021-03-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 195,768 2,784,279 7.56 23.00 4,502,586 64,037,303
2021-03-18 2021-03-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 53,061 3,566,396 1.51 23.00 1,220,382 82,025,681
2021-03-12 2021-03-10 4 CTIC CTI BIOPHARMA CORP
Stock Option (Right to Buy) 		A - Award 80,000 80,000
2021-03-08 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share 		3,372,098
2021-03-08 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share 		2,484,643
2021-03-08 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value per share 		405,344
2021-02-16 2021-02-11 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -152,127 534,847 -22.14 5.37 -816,709 2,871,380
2021-02-16 2021-02-11 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -892,467 3,279,831 -21.39 5.37 -4,791,298 17,608,101
2021-02-16 2021-02-11 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -1,215,491 4,448,421 -21.46 5.37 -6,525,485 23,881,793
2021-02-04 2021-02-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		S - Sale -4,325 233,150 -1.82 18.00 -77,850 4,196,700
2021-02-04 2021-02-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		S - Sale -16,850 1,188,131 -1.40 18.00 -303,300 21,386,358
2021-02-04 2021-02-02 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		S - Sale -25,234 1,642,186 -1.51 18.00 -454,212 29,559,348
2021-01-26 2021-01-22 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -568,019 686,974 -45.26 4.14 -2,350,917 2,843,248
2021-01-26 2021-01-22 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -2,458,838 4,172,298 -37.08 4.14 -10,176,639 17,268,307
2021-01-26 2021-01-22 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -2,821,663 5,663,912 -33.25 4.14 -11,678,299 23,441,799
2021-01-25 2021-01-21 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 43,422 426,206 11.34 24.75 1,074,694 10,548,598
2021-01-25 2021-01-21 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 343,444 2,588,511 15.30 24.75 8,500,239 64,065,647
2021-01-25 2021-01-21 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 457,814 3,513,335 14.98 24.75 11,330,896 86,955,041
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock 		C - Conversion -1,757 6,758 -20.63
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock 		C - Conversion -9,169 39,693 -18.77
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X1 Convertible Preferred Stock 		C - Conversion -11,776 52,145 -18.42
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred 		C - Conversion -35 0 -100.00
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred 		C - Conversion -203 0 -100.00
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Series X Convertible Preferred 		C - Conversion -273 0 -100.00
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		C - Conversion 97,615 113,152 628.27
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		C - Conversion 1,944 15,537 14.30
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		C - Conversion 509,410 598,624 571.00
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		C - Conversion 11,278 89,214 14.47
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		C - Conversion 654,215 771,780 556.47
2020-12-28 2020-12-22 4 NVUS Eledon Pharmaceuticals, Inc.
Common Stock, $0.001 par value 		C - Conversion 15,166 117,565 14.81
2020-12-28 3 CTMX CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share 		2,945,743
2020-12-28 3 CTMX CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share 		2,164,406
2020-12-28 3 CTMX CytomX Therapeutics, Inc.
Common Stock, $0.00001 par value per share 		358,450
2020-12-22 2020-12-18 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 45,032 2,245,067 2.05 16.05 722,764 36,033,325
2020-12-22 2020-12-18 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 114,968 3,055,521 3.91 16.05 1,845,236 49,041,112
2020-12-15 2020-12-11 4 XOMA XOMA Corp
8.625% Series A Cumulative Perpetual Preferred Stock 		P - Purchase 200,000 200,000 25.00 5,000,000 5,000,000
2020-12-11 2020-12-09 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		S - Sale -25,486 463,244 -5.21 18.00 -458,748 8,338,392
2020-12-11 2020-12-09 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		S - Sale -166,194 2,760,185 -5.68 18.00 -2,991,492 49,683,330
2020-12-11 2020-12-09 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		S - Sale -239,274 3,811,271 -5.91 18.00 -4,306,932 68,602,878
2020-12-04 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		4,050,545
2020-12-04 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		2,926,379
2020-12-04 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		488,730
2020-11-20 2020-11-20 4 CYTK CYTOKINETICS INC
Call Option 		J - Other -93 0 -100.00
2020-11-20 2020-11-20 4 CYTK CYTOKINETICS INC
Call Option 		J - Other -551 0 -100.00
2020-11-20 2020-11-20 4 CYTK CYTOKINETICS INC
Call Option 		J - Other -740 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock 		C - Conversion -73,399 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock 		C - Conversion -522,403 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series C Convertible Preferred Stock 		C - Conversion -760,155 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock 		C - Conversion -101,784 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock 		C - Conversion -673,281 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series B Convertible Preferred Stock 		C - Conversion -889,186 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock 		C - Conversion -185,908 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock 		C - Conversion -881,156 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Series A-1 Convertible Preferred Stock 		C - Conversion -1,129,404 0 -100.00
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 74,991 436,082 20.77 19.00 1,424,829 8,285,558
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 73,399 361,091 25.51
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 101,784 287,692 54.75
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 185,908 185,908
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 446,425 2,523,265 21.50 19.00 8,482,075 47,942,035
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 522,403 2,076,840 33.61
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 673,281 1,554,437 76.41
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 881,156 881,156
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		P - Purchase 613,918 3,392,663 22.09 19.00 11,664,442 64,460,597
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 760,155 2,778,745 37.66
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 889,186 2,018,590 78.73
2020-11-20 2020-11-19 4 OLMA Olema Pharmaceuticals, Inc.
Common stock, $0.0001 par value 		C - Conversion 1,129,404 1,129,404
2020-11-20 2020-11-18 4 OLMA Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) 		A - Award 21,520 21,520
2020-11-20 2020-11-18 4 OLMA Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) 		A - Award 21,520 21,520
2020-11-20 2020-11-18 4 OLMA Olema Pharmaceuticals, Inc.
Stock Option (Right to buy) 		A - Award 21,520 21,520
2020-11-16 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		3,822,766
2020-11-16 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		2,777,320
2020-11-16 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		465,924
2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		S - Sale -502,649 81,263 -86.08 20.19 -10,146,825 1,640,432
2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		S - Sale -2,949,477 485,513 -85.87 20.19 -59,540,207 9,800,905
2020-11-13 2020-11-11 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		S - Sale -3,941,214 670,695 -85.46 20.19 -79,560,105 13,539,119
2020-11-06 2020-11-04 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 86,090 630,453 15.81 2.60 223,834 1,639,178
2020-11-06 2020-11-04 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 506,155 3,712,350 15.79 2.60 1,316,003 9,652,110
2020-11-06 2020-11-04 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 674,492 4,980,812 15.66 2.60 1,753,679 12,950,111
2020-11-06 2020-11-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 2,334 583,912 0.40 4.98 11,633 2,910,217
2020-11-06 2020-11-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 10,436 3,434,990 0.30 4.98 52,013 17,119,990
2020-11-06 2020-11-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 17,230 4,611,909 0.37 4.98 85,874 22,985,754
2020-11-06 2020-11-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 15,355 581,578 2.71 4.88 74,997 2,840,543
2020-11-06 2020-11-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 143,403 3,424,554 4.37 4.88 700,409 16,726,207
2020-11-06 2020-11-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 257,804 4,594,679 5.94 4.88 1,259,166 22,441,331
2020-11-03 2020-10-30 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 15,472 544,363 2.93 2.75 42,548 1,496,998
2020-11-03 2020-10-30 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 250,755 3,206,195 8.48 2.75 689,576 8,817,036
2020-11-03 2020-10-30 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 666,385 4,306,320 18.31 2.75 1,832,559 11,842,380
2020-10-08 2020-10-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 25,107 566,223 4.64 5.04 126,414 2,850,933
2020-10-08 2020-10-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 162,352 3,281,151 5.21 5.04 817,442 16,520,595
2020-10-08 2020-10-06 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 157,782 4,336,875 3.78 5.04 794,432 21,836,166
2020-10-05 3 NVUS Novus Therapeutics, Inc.
Common Stock 		102,400
2020-10-05 3 NVUS Novus Therapeutics, Inc.
Common Stock 		77,936
2020-10-05 3 NVUS Novus Therapeutics, Inc.
Common Stock 		13,595
2020-09-24 2020-09-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 32 541,116 0.01 3.80 122 2,055,537
2020-09-23 2020-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 7,201 1,750,704 0.41 18.20 131,057 31,862,463
2020-09-23 2020-09-23 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 9,888 2,040,124 0.49 18.20 179,960 37,129,849
2020-09-23 2020-09-22 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 4,991 1,743,503 0.29 18.45 92,062 32,160,133
2020-09-23 2020-09-22 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 6,960 2,030,236 0.34 18.45 128,382 37,449,124
2020-09-23 2020-09-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 10,069 1,738,512 0.58 18.39 185,120 31,962,717
2020-09-23 2020-09-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 12,259 2,023,276 0.61 18.39 225,383 37,198,132
2020-09-17 2020-09-15 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 10,258 382,784 2.75 11.75 120,532 4,497,712
2020-09-17 2020-09-15 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 58,745 2,200,035 2.74 11.75 690,254 25,850,411
2020-09-17 2020-09-15 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 77,751 2,940,553 2.72 11.75 913,574 34,551,498
2020-09-14 2020-09-10 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 12,816 372,526 3.56 11.10 142,235 4,134,368
2020-09-14 2020-09-10 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 76,374 2,141,290 3.70 11.10 847,614 23,764,465
2020-09-14 2020-09-10 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 100,461 2,862,802 3.64 11.10 1,114,936 31,771,949
2020-09-10 2020-09-04 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,830 1,728,443 0.22 18.77 71,891 32,443,912
2020-09-10 2020-09-04 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,907 2,011,017 0.19 18.77 73,337 37,747,996
2020-09-08 2020-09-03 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 14,339 359,710 4.15 11.17 160,167 4,017,961
2020-09-08 2020-09-03 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 82,740 2,064,916 4.17 11.17 924,206 23,065,112
2020-09-08 2020-09-03 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 104,827 2,762,341 3.94 11.17 1,170,918 30,855,349
2020-09-01 2020-09-01 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 7,672 1,724,613 0.45 18.87 144,741 32,536,721
2020-09-01 2020-09-01 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 9,900 2,007,110 0.50 18.87 186,774 37,866,338
2020-09-01 2020-08-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 6,862 1,716,941 0.40 18.48 126,814 31,730,100
2020-09-01 2020-08-31 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 9,143 1,997,210 0.46 18.48 168,968 36,909,639
2020-09-01 2020-08-28 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 922 1,710,079 0.05 19.17 17,676 32,785,464
2020-09-01 2020-08-28 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 1,122 1,988,067 0.06 19.17 21,511 38,115,022
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Series C Preferred Stock 		C - Conversion -180,686 0 -100.00
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Series C Preferred Stock 		C - Conversion -1,000,955 0 -100.00
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Series C Preferred Stock 		C - Conversion -1,336,390 0 -100.00
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		A - Award 67,791 181,081 59.84 20.00 1,355,820 3,621,620
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		C - Conversion 113,290 113,290
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		A - Award 389,709 1,017,307 62.10 20.00 7,794,180 20,346,140
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		C - Conversion 627,598 627,598
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		A - Award 521,193 1,359,109 62.20 20.00 10,423,860 27,182,180
2020-08-25 2020-08-21 4 KYMR Kymera Therapeutics, Inc.
Common Stock, $0.0001 par value 		C - Conversion 837,916 837,916
2020-08-25 2020-08-20 4 KYMR Kymera Therapeutics, Inc.
Stock Option (Right to Buy) 		A - Award -40,127 40,127 -50.00
2020-08-25 2020-08-25 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 2,244 1,709,157 0.13 19.74 44,308 33,747,305
2020-08-25 2020-08-25 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,443 1,986,945 0.17 19.74 67,982 39,232,229
2020-08-25 2020-08-24 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 5,179 1,706,913 0.30 19.31 100,003 32,959,295
2020-08-25 2020-08-24 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 6,504 1,983,502 0.33 19.31 125,588 38,300,035
2020-08-25 2020-08-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 1,607 1,701,734 0.09 19.32 31,050 32,880,224
2020-08-25 2020-08-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 9,198 1,976,998 0.47 19.32 177,720 38,198,765
2020-08-20 2020-08-18 4 PRNB Principia Biopharma Inc.
Call Option (Right to Buy) 		P - Purchase 158 3,547 4.66 35.79 5,655 126,947
2020-08-20 2020-08-18 4 PRNB Principia Biopharma Inc.
Call Option (Right to Buy) 		P - Purchase 905 20,390 4.64 35.79 32,390 729,758
2020-08-20 2020-08-18 4 PRNB Principia Biopharma Inc.
Call Option (Right to Buy) 		P - Purchase 1,205 27,265 4.62 35.79 43,127 975,814
2020-08-20 2020-08-20 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 1,772 1,967,800 0.09 19.12 33,881 37,624,336
2020-08-20 2020-08-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,496 1,966,028 0.18 19.70 68,877 38,733,897
2020-08-20 2020-08-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 895 1,962,532 0.05 19.27 17,246 37,816,814
2020-08-14 2020-08-14 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 21,922 1,961,637 1.13 18.69 409,810 36,670,842
2020-08-14 2020-08-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 1,050 1,939,715 0.05 17.80 18,693 34,533,134
2020-08-14 2020-08-12 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 4,050 1,938,665 0.21 17.34 70,233 33,619,359
2020-07-02 2020-06-30 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 81 237,475 0.03 13.32 1,079 3,162,312
2020-07-02 2020-06-30 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 929 1,204,981 0.08 13.32 12,371 16,046,009
2020-07-02 2020-06-30 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 1,521 1,667,420 0.09 13.32 20,254 22,204,032
2020-06-22 2020-06-22 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 1,354 237,394 0.57 13.93 18,868 3,308,014
2020-06-22 2020-06-22 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 7,854 1,204,052 0.66 13.93 109,443 16,778,103
2020-06-22 2020-06-22 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 10,524 1,665,899 0.64 13.93 146,649 23,213,803
2020-06-22 2020-06-19 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 6,769 236,040 2.95 14.39 97,403 3,396,498
2020-06-22 2020-06-19 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 39,052 1,196,198 3.37 14.39 561,939 17,212,691
2020-06-22 2020-06-19 4 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 52,443 1,655,375 3.27 14.39 754,629 23,820,019
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,592,281
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		4,146,495
2020-06-22 3 IDYA IDEAYA Biosciences, Inc.
Common Stock, $0.0001 par value 		3,218,620
2020-06-10 2020-06-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 6,967 345,371 2.06 15.20 105,898 5,249,639
2020-06-10 2020-06-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 33,321 1,982,176 1.71 15.20 506,479 30,129,075
2020-06-10 2020-06-08 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 46,966 2,657,514 1.80 15.20 713,883 40,394,213
2020-06-03 2020-06-01 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 94,101 338,404 38.52 14.00 1,317,414 4,737,656
2020-06-03 2020-06-01 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 561,966 1,948,855 40.52 14.00 7,867,524 27,283,970
2020-06-03 2020-06-01 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 806,443 2,610,548 44.70 14.00 11,290,202 36,547,672
2020-05-26 2020-05-21 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		S - Sale -192,250 480,432 -28.58 6.00 -1,153,500 2,882,592
2020-05-26 2020-05-21 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		S - Sale -1,064,332 2,766,561 -27.78 6.00 -6,385,992 16,599,366
2020-05-26 2020-05-21 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		S - Sale -1,027,016 3,712,340 -21.67 6.00 -6,162,096 22,274,040
2020-05-18 2020-05-14 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 4,476 541,084 0.83 4.10 18,352 2,218,444
2020-05-18 2020-05-14 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 39,810 3,118,799 1.29 4.10 163,221 12,787,076
2020-05-18 2020-05-14 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 249,301 4,179,093 6.34 4.10 1,022,134 17,134,281
2020-04-17 2020-04-15 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock 		C - Conversion -597 0 -100.00
2020-04-17 2020-04-15 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock 		C - Conversion -656 0 -100.00
2020-04-17 2020-04-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		C - Conversion 596,813 1,700,127 54.09 13.00 7,758,569 22,101,651
2020-04-17 2020-04-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		C - Conversion 655,959 1,934,615 51.30 13.00 8,527,467 25,149,995
2020-03-27 2020-03-25 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 8,264 1,278,656 0.65 17.20 142,129 21,991,093
2020-03-20 2020-03-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 4,439 1,270,392 0.35 14.52 64,475 18,451,936
2020-03-17 2020-03-17 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 8,113 1,265,953 0.64 15.73 127,648 19,918,125
2020-03-17 2020-03-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 10,164 1,257,840 0.81 15.73 159,916 19,790,351
2020-03-17 2020-03-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 100,000 1,247,676 8.71 18.34 1,834,090 22,883,501
2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock 		P - Purchase 12 12
2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock 		P - Purchase 87 191 83.65
2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock 		P - Purchase 841 1,250 205.62
2020-03-04 2020-03-04 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock 		P - Purchase 981 1,594 160.03
2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock 		X - Other 104 104
2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Subscription Rights (right to buy) 		X - Other -104 0 -100.00
2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock 		X - Other 409 409
2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Subscription Rights (right to buy) 		X - Other -409 0 -100.00
2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Series X Convertible Preferred Stock 		X - Other 613 613
2020-03-04 2020-03-02 4 CTIC CTI BIOPHARMA CORP
Subscription Rights (right to buy) 		X - Other -613 0 -100.00
2020-02-18 2020-02-13 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		S - Sale -74,893 424,419 -15.00 15.79 -1,182,321 6,700,218
2020-02-18 2020-02-13 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		S - Sale -510,793 2,350,829 -17.85 15.79 -8,063,787 37,112,067
2020-02-18 2020-02-13 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		S - Sale -486,344 3,131,432 -13.44 15.79 -7,677,815 49,435,291
2020-01-21 2020-01-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 19,727 244,303 8.78 16.15 318,591 3,945,493
2020-01-21 2020-01-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 112,561 1,386,889 8.83 16.15 1,817,860 22,398,257
2020-01-21 2020-01-16 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 146,442 1,804,105 8.83 16.15 2,365,038 29,136,296
2020-01-15 2020-01-13 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 5,406 224,576 2.47 14.98 80,973 3,363,789
2020-01-15 2020-01-13 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 25,108 1,274,328 2.01 14.98 376,078 19,087,395
2020-01-15 2020-01-13 4 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		P - Purchase 53,448 1,657,663 3.33 14.98 800,566 24,829,139
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,676,820
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		4,321,825
2020-01-13 3 MRUS Merus N.V.
Common Shares, (euro)0.09 nominal value per share 		3,291,775
2019-12-26 2019-12-20 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 32,606 536,608 6.47 4.05 132,054 2,173,262
2019-12-26 2019-12-20 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 201,096 3,078,989 6.99 4.05 814,439 12,469,905
2019-12-26 2019-12-20 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 281,318 3,929,792 7.71 4.05 1,139,338 15,915,658
2019-12-20 2019-12-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 165,961 1,103,314 17.71 22.00 3,651,142 24,272,908
2019-12-20 2019-12-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 207,234 1,147,676 22.04 22.00 4,559,148 25,248,872
2019-12-20 2019-12-18 4 XOMA XOMA Corp
Subscription Rights (right to buy) 		X - Other -35,888 0 -100.00
2019-12-20 2019-12-18 4 XOMA XOMA Corp
Subscription Rights (right to buy) 		X - Other -190,899 0 -100.00
2019-12-20 2019-12-18 4 XOMA XOMA Corp
Subscription Rights (right to buy) 		X - Other -245,481 0 -100.00
2019-12-20 2019-12-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		X - Other 35,888 159,537 29.02 22.00 789,536 3,509,814
2019-12-20 2019-12-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		X - Other 190,899 937,353 25.57 22.00 4,199,778 20,621,766
2019-12-20 2019-12-18 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		X - Other 245,481 940,442 35.32 22.00 5,400,582 20,689,724
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		10,080,782
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		9,353,356
2019-12-12 3 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		7,112,414
2019-12-12 2019-12-11 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		P - Purchase 8,506 499,312 1.73 9.52 80,935 4,750,954
2019-12-12 2019-12-11 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		P - Purchase 49,804 2,861,622 1.77 9.52 473,885 27,228,333
2019-12-12 2019-12-11 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		P - Purchase 60,103 3,617,776 1.69 9.52 571,880 34,423,139
2019-12-12 2019-12-10 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		P - Purchase 15,030 490,806 3.16 9.40 141,282 4,613,576
2019-12-12 2019-12-10 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		P - Purchase 95,100 2,811,818 3.50 9.40 893,940 26,431,089
2019-12-12 2019-12-10 4 CYTK CYTOKINETICS INC
Common Stock, $0.001 par value 		P - Purchase 113,529 3,557,673 3.30 9.40 1,067,173 33,442,126
2019-12-11 2019-12-09 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 2,397 504,002 0.48 4.02 9,630 2,024,828
2019-12-11 2019-12-09 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 18,729 2,877,893 0.66 4.02 75,244 11,561,935
2019-12-11 2019-12-09 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 113,874 3,648,474 3.22 4.02 457,489 14,657,744
2019-11-26 2019-11-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 81,857 501,605 19.50 3.40 278,322 1,705,507
2019-11-26 2019-11-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 462,056 2,859,164 19.28 3.40 1,571,037 9,721,444
2019-11-26 2019-11-22 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 576,097 3,534,600 19.47 3.40 1,958,787 12,017,993
2019-11-22 2019-11-20 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 14,151 672,682 2.15 3.91 55,353 2,631,263
2019-11-22 2019-11-20 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 79,285 3,830,893 2.11 3.91 310,131 14,984,921
2019-11-22 2019-11-20 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 98,518 4,739,356 2.12 3.91 385,363 18,538,465
2019-11-18 2019-11-14 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 11,105 658,531 1.72 3.37 37,424 2,219,249
2019-11-18 2019-11-14 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 45,888 3,751,608 1.24 3.37 154,643 12,642,919
2019-11-18 2019-11-14 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 71,495 4,640,838 1.56 3.37 240,938 15,639,624
2019-11-07 2019-11-05 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 70,921 419,748 20.33 4.00 283,684 1,678,992
2019-11-07 2019-11-05 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 400,470 2,397,108 20.06 4.00 1,601,880 9,588,432
2019-11-07 2019-11-05 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 496,721 2,958,503 20.18 4.00 1,986,884 11,834,012
2019-10-31 2019-10-30 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 57,868 647,426 9.82 2.70 156,244 1,748,050
2019-10-31 2019-10-30 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 331,048 3,705,720 9.81 2.70 893,830 10,005,444
2019-10-31 2019-10-30 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 408,592 4,569,343 9.82 2.70 1,103,198 12,337,226
2019-10-31 2019-10-29 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 116,552 589,558 24.64 2.60 303,035 1,532,851
2019-10-31 2019-10-29 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 610,052 3,374,672 22.07 2.60 1,586,135 8,774,147
2019-10-31 2019-10-29 4 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		P - Purchase 872,373 4,160,751 26.53 2.60 2,268,170 10,817,953
2019-10-31 2019-10-31 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 504 348,827 0.14 3.85 1,940 1,342,844
2019-10-31 2019-10-31 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 2,913 1,996,638 0.15 3.85 11,214 7,686,258
2019-10-31 2019-10-31 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 3,416 2,461,782 0.14 3.85 13,150 9,476,876
2019-10-31 2019-10-30 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,456 348,323 0.42 3.89 5,667 1,355,708
2019-10-31 2019-10-30 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 8,236 1,993,725 0.41 3.89 32,055 7,759,777
2019-10-31 2019-10-30 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 10,389 2,458,366 0.42 3.89 40,435 9,568,206
2019-10-31 2019-10-29 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 240 346,867 0.07 3.90 935 1,351,706
2019-10-31 2019-10-29 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,133 1,985,489 0.06 3.90 4,415 7,737,252
2019-10-31 2019-10-29 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,027 2,447,977 0.04 3.90 4,002 9,539,522
2019-10-25 2019-10-25 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 2,155 346,627 0.63 3.75 8,075 1,298,915
2019-10-25 2019-10-25 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 12,899 1,984,356 0.65 3.75 48,336 7,435,977
2019-10-25 2019-10-25 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 15,728 2,446,950 0.65 3.75 58,938 9,169,456
2019-10-25 2019-10-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,629 344,472 0.48 3.74 6,100 1,289,944
2019-10-25 2019-10-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 57,723 1,971,457 3.02 3.74 216,155 7,382,515
2019-10-25 2019-10-24 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 76,036 2,431,222 3.23 3.74 284,732 9,104,197
2019-10-25 2019-10-23 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 3,200 2,355,186 0.14 3.75 11,986 8,821,349
2019-10-08 2019-10-08 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 4,689 342,843 1.39 3.68 17,270 1,262,691
2019-10-08 2019-10-08 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 24,716 1,913,734 1.31 3.68 91,029 7,048,282
2019-10-08 2019-10-08 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 31,007 2,351,986 1.34 3.68 114,199 8,662,364
2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 24,425 338,154 7.79 3.75 91,594 1,268,078
2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 14,242 313,729 4.76 3.75 53,382 1,175,919
2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 138,609 1,889,018 7.92 3.75 519,784 7,083,818
2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 80,821 1,750,409 4.84 3.75 302,933 6,560,883
2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 168,640 2,320,979 7.84 3.75 632,400 8,703,671
2019-10-08 2019-10-07 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 98,333 2,152,339 4.79 3.75 368,572 8,067,397
2019-10-08 2019-10-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 991 299,487 0.33 3.74 3,704 1,119,333
2019-10-08 2019-10-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 7,314 1,669,588 0.44 3.74 27,336 6,240,085
2019-10-08 2019-10-04 4 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		P - Purchase 7,695 2,054,006 0.38 3.74 28,760 7,676,847
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		6,053,392
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		5,669,355
2019-10-02 3 FPRX FIVE PRIME THERAPEUTICS, INC.
Common Stock, $0.001 par value 		4,305,577
2019-09-10 2019-09-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -1,128 314,139 -0.36 4.50 -5,075 1,413,437
2019-09-10 2019-09-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -25,720 2,233,074 -1.14 4.50 -115,725 10,047,493
2019-09-10 2019-09-06 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -23,152 2,385,055 -0.96 4.50 -104,170 10,731,316
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,390,475
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,241,062
2019-09-10 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,297,535
2019-09-09 2019-09-05 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 124,956 528,891 30.93 3.18 397,610 1,682,931
2019-09-09 2019-09-05 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 689,834 2,955,440 30.45 3.18 2,195,052 9,404,210
2019-09-09 2019-09-05 4 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		P - Purchase 853,956 3,639,935 30.65 3.18 2,717,288 11,582,273
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		8,241,499
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		7,721,126
2019-08-26 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value 		5,859,455
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,814,382
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		9,290,624
2019-07-01 3 CALA Calithera Biosciences, Inc.
Common Stock, $0.0001 par value 		6,999,010
2019-06-12 2019-06-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -29,450 169,589 -14.80 10.70 -315,230 1,815,264
2019-06-12 2019-06-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -158,583 952,859 -14.27 10.70 -1,697,457 10,199,307
2019-06-12 2019-06-10 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -198,256 1,178,904 -14.40 10.70 -2,122,112 12,618,871
2019-05-14 2019-05-14 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 13,816 746,454 1.89 14.74 203,664 11,003,628
2019-05-14 2019-05-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 3,797 732,638 0.52 14.36 54,526 10,520,975
2019-05-14 2019-05-10 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 10,300 728,841 1.43 14.57 150,037 10,616,808
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		4,064,801
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		3,799,083
2019-04-02 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		2,886,680
2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value 		J - Other 284 284
2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value 		J - Other 2,143 2,143
2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Series B Convertible Preferred Stock, $0.001 par value 		J - Other 2,573 2,573
2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		J - Other -284,000 141,346 -66.77
2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		J - Other -2,143,000 772,324 -73.51
2019-02-01 2019-01-30 4 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		J - Other -2,573,000 978,200 -72.45
2018-12-19 2018-12-18 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock 		X - Other 372 597 165.47 13,000.00 4,836,000 7,758,569
2018-12-19 2018-12-18 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock 		X - Other 311 656 89.96 13,000.00 4,038,398 8,527,467
2018-12-19 2018-12-17 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 25,000 718,541 3.60 14.19 354,792 10,197,318
2018-12-19 2018-12-14 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock 		X - Other 225 225 13,000.00 2,922,569 2,922,569
2018-12-19 2018-12-14 4 XOMA XOMA Corp
Subscription Rights 		X - Other -225 0 -100.00
2018-12-19 2018-12-14 4 XOMA XOMA Corp
Series Y Convertible Preferred Stock 		X - Other 345 345 13,000.00 4,489,069 4,489,069
2018-12-19 2018-12-14 4 XOMA XOMA Corp
Subscription Rights 		X - Other -345 0 -100.00
2018-12-17 2018-12-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 120,539 6,631,136 1.85 1.20 144,587 7,954,048
2018-12-17 2018-12-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 54,461 8,485,575 0.65 1.20 65,326 10,178,447
2018-12-13 2018-12-13 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 24,253 693,541 3.62 14.41 349,525 9,995,035
2018-12-13 2018-12-12 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 2,810 669,288 0.42 14.75 41,448 9,871,998
2018-12-13 2018-12-11 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 9,400 666,478 1.43 14.50 136,270 9,661,798
2018-12-10 2018-12-10 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 18,081 657,078 2.83 14.54 262,972 9,556,608
2018-12-10 2018-12-07 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 32,015 638,997 5.27 14.77 472,778 9,436,324
2018-12-10 2018-12-06 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 10,927 606,982 1.83 14.80 161,698 8,982,120
2018-12-04 2018-12-04 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 4,171 596,055 0.70 14.99 62,515 8,933,672
2018-12-04 2018-12-03 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 806 591,884 0.14 14.90 12,009 8,819,072
2018-12-04 2018-11-30 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 4,823 591,078 0.82 14.85 71,615 8,776,681
2018-12-04 2018-12-04 4 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		S - Sale -89,948 370,391 -19.54 1.83 -164,929 679,149
2018-12-04 2018-12-04 4 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		S - Sale -382,017 1,942,764 -16.43 1.83 -700,466 3,562,252
2018-12-04 2018-12-04 4 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		S - Sale -430,035 2,502,758 -14.66 1.83 -788,512 4,589,057
2018-11-30 2018-11-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 100,000 6,510,597 1.56 1.30 130,000 8,463,776
2018-11-29 2018-11-29 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 10,016 586,255 1.74 14.93 149,543 8,753,022
2018-11-29 2018-11-28 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 8,288 576,239 1.46 15.11 125,262 8,709,046
2018-11-29 2018-11-27 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 11,396 567,951 2.05 15.24 173,680 8,655,800
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		10,443,070
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		9,807,194
2018-11-26 3 PIRS PIERIS PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,317,216
2018-11-21 2018-11-21 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 25,000 556,555 4.70 15.00 374,892 8,345,932
2018-11-21 2018-11-20 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 37,482 531,555 7.59 13.68 512,701 7,270,928
2018-11-21 2018-11-19 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 9,771 494,073 2.02 13.93 136,064 6,880,115
2018-11-21 2018-11-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 581 1,254,993 0.05 1.35 784 1,694,241
2018-11-21 2018-11-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 4,119 8,431,114 0.05 1.35 5,561 11,382,004
2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 5,573 1,254,412 0.45 1.35 7,524 1,693,456
2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 38,001 6,410,597 0.60 1.35 51,301 8,654,306
2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 50,044 8,426,995 0.60 1.35 67,559 11,376,443
2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 81,648 1,248,839 7.00 1.37 111,841 1,710,660
2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 556,709 6,372,596 9.57 1.37 762,580 8,729,182
2018-11-21 2018-11-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 733,151 8,376,951 9.59 1.37 1,004,270 11,474,747
2018-11-19 2018-11-16 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 10,849 484,302 2.29 13.82 149,986 6,695,427
2018-11-19 2018-11-15 4 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		P - Purchase 21,141 473,453 4.67 13.31 281,361 6,301,091
2018-11-15 2018-11-15 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 39,074 5,815,887 0.68 1.35 52,750 7,851,447
2018-11-15 2018-11-15 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 52,400 7,643,800 0.69 1.35 70,740 10,319,130
2018-11-15 2018-11-14 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 92,960 5,776,813 1.64 1.34 124,566 7,740,929
2018-11-15 2018-11-14 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 117,290 7,591,400 1.57 1.34 157,169 10,172,476
2018-11-15 2018-11-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 562,754 5,683,853 10.99 1.35 759,718 7,673,202
2018-11-15 2018-11-13 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 41,454 7,474,110 0.56 1.35 55,963 10,090,048
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,650,706
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		8,042,694
2018-11-09 3 IMDZ IMMUNE DESIGN CORP.
Common Stock, $0.001 par value 		6,178,252
2018-06-21 2018-06-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 36,825 1,167,191 3.26 1.65 60,761 1,925,865
2018-06-21 2018-06-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 158,151 5,121,099 3.19 1.65 260,949 8,449,813
2018-06-21 2018-06-21 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 230,555 7,432,656 3.20 1.65 380,416 12,263,882
2018-06-21 2018-06-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 179,893 1,130,366 18.93 1.65 296,823 1,865,104
2018-06-21 2018-06-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,419,907 4,962,948 40.08 1.65 2,342,847 8,188,864
2018-06-21 2018-06-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,916,760 7,202,101 36.27 1.65 3,162,654 11,883,467
2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Warrants 		J - Other 188,746 188,746
2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Warrants 		J - Other 705,863 705,863
2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Warrants 		J - Other 1,105,391 1,105,391
2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		J - Other -188,746 85,038 -68.94
2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		J - Other -705,863 318,021 -68.94
2018-06-20 2018-06-18 4 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		J - Other -1,105,391 498,025 -68.94
2018-06-01 2018-05-30 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -175,813 771,305 -18.56 5.00 -879,083 3,856,602
2018-06-01 2018-05-30 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -312,266 3,186,044 -8.93 5.00 -1,561,361 15,930,539
2018-06-01 2018-05-30 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -547,860 4,682,669 -10.47 5.00 -2,739,355 23,413,813
2018-04-20 2018-04-18 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -217,256 947,118 -18.66 3.10 -673,494 2,936,066
2018-04-20 2018-04-18 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -808,449 3,498,310 -18.77 3.10 -2,506,192 10,844,761
2018-04-20 2018-04-18 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -1,204,668 5,230,529 -18.72 3.10 -3,734,471 16,214,640
2018-04-11 2018-04-10 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 97,453 950,473 11.42 2.00 194,906 1,900,946
2018-04-11 2018-04-10 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 365,682 3,543,041 11.51 2.00 731,364 7,086,082
2018-04-11 2018-04-10 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 546,865 5,285,341 11.54 2.00 1,093,730 10,570,682
2018-04-11 2018-04-09 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 62,437 853,020 7.90 1.90 118,630 1,620,738
2018-04-11 2018-04-09 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 208,872 3,177,359 7.04 1.90 396,857 6,036,982
2018-04-11 2018-04-09 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 228,691 4,738,476 5.07 1.90 434,513 9,003,104
2018-04-06 2018-04-04 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -214,336 1,164,374 -15.55 2.90 -621,574 3,376,685
2018-04-06 2018-04-04 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -817,611 4,306,759 -15.96 2.90 -2,371,072 12,489,601
2018-04-06 2018-04-04 4 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		S - Sale -1,269,634 6,435,197 -16.48 2.90 -3,681,939 18,662,071
2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares 		J - Other 238,000 238,000
2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares 		J - Other 861,000 861,000
2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Series 1 Preferred Shares 		J - Other 1,338,000 1,338,000
2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Common Shares, no par value per share 		J - Other -238,000 59,464 -80.01
2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Common Shares, no par value per share 		J - Other -861,000 216,694 -79.89
2018-03-29 2018-03-27 4 XENE Xenon Pharmaceuticals Inc.
Common Shares, no par value per share 		J - Other -1,338,000 336,468 -79.91
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock 		A - Award 2,280 2,280
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock 		A - Award 1,024 1,024
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock 		A - Award 3,640 3,640
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series O Preferred Stock 		A - Award 5,631 5,631
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock 		D - Sale to Issuer -49 0 -100.00
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock 		D - Sale to Issuer -48 0 -100.00
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock 		D - Sale to Issuer -197 0 -100.00
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Series N Preferred Stock 		D - Sale to Issuer -281 0 -100.00
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		P - Purchase 699,225 1,295,582 117.25 3.00 2,097,675 3,886,746
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		P - Purchase 483,708 483,708 3.00 1,451,124 1,451,124
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		P - Purchase 2,109,280 2,109,280 3.00 6,327,840 6,327,840
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		P - Purchase 3,041,120 3,041,120 3.00 9,123,360 9,123,360
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		D - Sale to Issuer -1,487,294 596,357 -71.38
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		D - Sale to Issuer -651,074 0 -100.00
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		D - Sale to Issuer -2,295,083 0 -100.00
2018-02-12 2018-02-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, par value $0.001 		D - Sale to Issuer -3,566,549 0 -100.00
2017-12-21 2017-12-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -169,292 122,496 -58.02 26.65 -4,511,632 3,264,518
2017-12-21 2017-12-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -445,615 632,642 -41.33 26.65 -11,875,640 16,859,909
2017-12-21 2017-12-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		S - Sale -667,949 951,300 -41.25 26.65 -17,800,841 25,352,145
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		4,504,500
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,924,968
2017-12-08 3 SNDX Syndax Pharmaceuticals Inc
Common Stock, $0.0001 par value per share 		3,174,868
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		17,248,837
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		15,027,176
2017-11-27 3 RGLS Regulus Therapeutics Inc.
Common Stock, $0.001 par value per share 		12,158,047
2017-10-23 2017-10-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 34,632 291,788 13.47 15.84 548,484 4,621,192
2017-10-23 2017-10-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 135,206 1,078,257 14.34 15.84 2,141,325 17,076,895
2017-10-23 2017-10-19 4 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 162,078 1,619,249 11.12 15.84 2,566,910 25,644,856
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		21,912,742
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		19,332,281
2017-10-20 3 ARQL ARQULE INC
Common Stock, $0.01 par value per share 		15,586,621
2017-10-05 2017-10-04 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 63,042 790,583 8.67 1.28 80,946 1,015,109
2017-10-05 2017-10-04 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 235,326 2,968,487 8.61 1.28 302,159 3,811,537
2017-10-05 2017-10-04 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 355,081 4,509,785 8.55 1.28 455,924 5,790,564
2017-10-05 2017-10-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 28,918 727,541 4.14 1.24 35,714 898,513
2017-10-05 2017-10-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 394,078 2,733,161 16.85 1.24 486,686 3,375,454
2017-10-05 2017-10-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 523,601 4,154,704 14.42 1.24 646,647 5,131,059
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		4,114,549
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		3,600,429
2017-09-29 3 CNCE CONCERT PHARMACEUTICALS, INC.
Common Stock, $0.001 par value per share 		2,914,534
2017-08-16 2017-08-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 7,429 1,077,694 0.69 2.41 17,920 2,599,613
2017-08-16 2017-08-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 11,429 1,674,468 0.69 2.41 27,569 4,039,152
2017-08-16 2017-08-14 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 13,337 1,070,265 1.26 2.70 36,058 2,893,568
2017-08-16 2017-08-14 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 28,007 1,663,039 1.71 2.70 75,720 4,496,192
2017-07-18 2017-07-14 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value 		S - Sale -105,713 890,487 -10.61 0.06 -6,343 53,429
2017-07-18 2017-07-14 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value 		S - Sale -242,236 1,377,652 -14.95 0.06 -14,534 82,659
2017-07-18 2017-07-14 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value 		S - Sale -3,993,637 0 -100.00 0.06 -239,618
2017-06-30 2017-06-27 4/A XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 8,496 297,464 2.94 3.04 25,795 903,130
2017-06-30 2017-06-27 4/A XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 30,170 1,056,928 2.94 3.04 91,599 3,208,939
2017-06-30 2017-06-27 4/A XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 46,795 1,635,032 2.95 3.04 142,074 4,964,121
2017-06-29 2017-06-27 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 8,496 297,464 2.94 4.00 33,984 1,189,856
2017-06-29 2017-06-27 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 30,170 1,056,928 2.94 4.00 120,680 4,227,712
2017-06-29 2017-06-27 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 46,795 1,635,032 2.95 4.00 187,180 6,540,128
2017-06-23 2017-06-22 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 854 288,968 0.30 4.00 3,416 1,155,872
2017-06-23 2017-06-22 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 2,884 1,026,758 0.28 4.00 11,536 4,107,032
2017-06-23 2017-06-22 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 4,525 1,588,237 0.29 4.00 18,100 6,352,948
2017-06-23 2017-06-21 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 1,362 288,114 0.47 4.00 5,448 1,152,456
2017-06-23 2017-06-21 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 4,406 1,023,874 0.43 4.00 17,624 4,095,496
2017-06-23 2017-06-21 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 6,380 1,583,712 0.40 4.00 25,520 6,334,848
2017-06-22 2017-06-20 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 1,715 201,811 0.86 2.25 3,859 454,075
2017-06-22 2017-06-20 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 6,359 717,089 0.89 2.25 14,308 1,613,450
2017-06-22 2017-06-20 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 9,732 1,109,258 0.89 2.25 21,897 2,495,830
2017-06-19 2017-06-19 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 357 286,752 0.12 3.85 1,374 1,103,995
2017-06-19 2017-06-19 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 1,271 1,019,468 0.12 3.85 4,893 3,924,952
2017-06-19 2017-06-19 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 1,967 1,577,332 0.12 3.85 7,573 6,072,728
2017-06-19 2017-06-16 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 1,064 286,395 0.37 3.85 4,096 1,102,621
2017-06-19 2017-06-16 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 3,873 1,018,197 0.38 3.85 14,911 3,920,058
2017-06-19 2017-06-16 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 6,097 1,575,365 0.39 3.85 23,473 6,065,155
2017-06-19 2017-06-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 1,160 285,331 0.41 3.84 4,451 1,094,815
2017-06-19 2017-06-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 3,845 1,014,324 0.38 3.84 14,753 3,891,961
2017-06-19 2017-06-15 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 6,774 1,569,268 0.43 3.84 25,992 6,021,281
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		C - Conversion -536 49 -91.62
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		C - Conversion -513 48 -91.44
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		C - Conversion -2,115 197 -91.48
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		C - Conversion -3,011 281 -91.46
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		P - Purchase 585 585
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		P - Purchase 561 561
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		P - Purchase 2,312 2,312
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Series N3 Preferred Stock, no par value per share 		P - Purchase 3,292 3,292
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		C - Conversion 357,333 2,083,651 20.70
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		C - Conversion 342,000 651,074 110.65
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		C - Conversion 1,410,000 2,295,083 159.31
2017-06-14 2017-06-09 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		C - Conversion 2,007,333 3,566,549 128.74
2017-06-08 2017-06-07 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 20,594 284,171 7.81 3.85 79,312 1,094,399
2017-06-08 2017-06-07 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 73,749 1,010,479 7.87 3.85 284,022 3,891,557
2017-06-08 2017-06-07 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 113,446 1,562,494 7.83 3.85 436,903 6,017,477
2017-06-08 2017-06-06 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 913 263,577 0.35 3.75 3,424 988,414
2017-06-08 2017-06-06 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 53,260 936,730 6.03 3.75 199,725 3,512,738
2017-06-08 2017-06-06 4 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		P - Purchase 96,736 1,449,048 7.15 3.75 362,760 5,433,930
2017-06-07 2017-06-07 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 3,673 200,096 1.87 2.28 8,379 456,479
2017-06-07 2017-06-07 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 13,046 710,730 1.87 2.28 29,762 1,621,388
2017-06-07 2017-06-07 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 20,181 1,099,526 1.87 2.28 46,039 2,508,349
2017-06-07 2017-06-05 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 3,920 196,423 2.04 2.29 8,979 449,927
2017-06-07 2017-06-05 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 12,624 697,684 1.84 2.29 28,917 1,598,115
2017-06-07 2017-06-05 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 19,206 1,079,345 1.81 2.29 43,993 2,472,348
2017-06-01 2017-05-31 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 2,727 192,503 1.44 2.25 6,128 432,554
2017-06-01 2017-05-31 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 10,023 685,060 1.48 2.25 22,522 1,539,330
2017-06-01 2017-05-31 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 15,350 1,060,139 1.47 2.25 34,491 2,382,132
2017-06-01 2017-05-30 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 1,805 189,776 0.96 2.30 4,144 435,669
2017-06-01 2017-05-30 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 6,903 675,037 1.03 2.30 15,847 1,549,682
2017-06-01 2017-05-30 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 10,192 1,044,789 0.99 2.30 23,398 2,398,522
2017-05-19 2017-05-19 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 1,124 187,971 0.60 2.30 2,585 432,333
2017-05-19 2017-05-19 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 4,223 668,134 0.64 2.30 9,713 1,536,708
2017-05-19 2017-05-19 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 6,253 1,034,597 0.61 2.30 14,382 2,379,573
2017-05-19 2017-05-18 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 2,909 186,847 1.58 2.30 6,690 429,711
2017-05-19 2017-05-18 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 10,541 663,911 1.61 2.30 24,242 1,526,863
2017-05-19 2017-05-18 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 16,436 1,028,344 1.62 2.30 37,800 2,364,986
2017-05-19 2017-05-17 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 5,510 183,938 3.09 2.30 12,666 422,818
2017-05-19 2017-05-17 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 6,897 653,370 1.07 2.30 15,854 1,501,902
2017-05-19 2017-05-17 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 24,965 1,011,908 2.53 2.30 57,387 2,326,073
2017-05-11 2017-05-11 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 675 178,428 0.38 2.34 1,581 418,039
2017-05-11 2017-05-11 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 2,565 646,473 0.40 2.34 6,010 1,514,622
2017-05-11 2017-05-11 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 3,794 986,943 0.39 2.34 8,889 2,312,309
2017-05-11 2017-05-10 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 6,217 177,753 3.62 2.35 14,583 416,955
2017-05-11 2017-05-10 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 22,092 643,908 3.55 2.35 51,821 1,510,415
2017-05-11 2017-05-10 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 33,691 983,149 3.55 2.35 79,029 2,306,173
2017-05-11 2017-05-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 3,929 171,536 2.34 2.29 8,989 392,457
2017-05-11 2017-05-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 14,274 621,816 2.35 2.29 32,657 1,422,653
2017-05-11 2017-05-09 4 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value 		P - Purchase 21,797 949,458 2.35 2.29 49,869 2,172,265
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,630,471
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		2,310,352
2017-05-11 3 NVLS Nivalis Therapeutics, Inc.
Common Stock, $0.001 par value per share 		1,870,417
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,665,288
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		4,098,367
2017-05-11 3 GLYC GLYCOMIMETICS INC
Common Stock, $0.001 par value per share 		3,319,001
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		2,197,761
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,955,112
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,626,449
2017-02-21 3 XOMA XOMA Corp
Common Stock, $0.0075 par value per share 		1,734,678
2017-01-05 2017-01-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 3,234 2,339,083 0.14 1.34 4,333 3,133,669
2017-01-05 2017-01-03 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,145 3,631,103 0.03 1.34 1,534 4,864,589
2016-12-30 2016-12-30 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 1,205 2,335,849 0.05 1.34 1,614 3,129,103
2016-12-30 2016-12-30 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 2,348 3,629,958 0.06 1.34 3,145 4,862,692
2016-12-30 2016-12-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 77,076 698,623 12.40 1.34 102,943 933,081
2016-12-30 2016-12-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 260,046 2,334,644 12.53 1.34 347,317 3,118,151
2016-12-30 2016-12-28 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 401,726 3,627,610 12.45 1.34 536,545 4,845,036
2016-12-20 2016-12-20 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 2,244 621,547 0.36 1.35 3,040 842,134
2016-12-20 2016-12-20 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 8,111 2,074,598 0.39 1.35 10,990 2,810,873
2016-12-20 2016-12-20 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 11,646 3,225,884 0.36 1.35 15,779 4,370,750
2016-12-20 2016-12-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 21,021 619,303 3.51 1.36 28,555 841,261
2016-12-20 2016-12-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 69,041 2,066,487 3.46 1.36 93,785 2,807,116
2016-12-20 2016-12-19 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 108,202 3,214,238 3.48 1.36 146,982 4,366,221
2016-12-20 2016-12-16 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 47,812 598,282 8.69 1.28 61,199 765,801
2016-12-20 2016-12-16 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 150,451 1,997,446 8.15 1.28 192,577 2,556,731
2016-12-20 2016-12-16 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 236,393 3,106,036 8.24 1.28 302,583 3,975,726
2016-12-02 2016-12-02 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 2,916 550,470 0.53 1.19 3,470 655,114
2016-12-02 2016-12-02 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 18,586 1,846,995 1.02 1.19 22,119 2,198,109
2016-12-02 2016-12-02 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 30,998 2,869,643 1.09 1.19 36,891 3,415,162
2016-12-02 2016-12-01 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 15,161 547,554 2.85 1.18 17,958 648,578
2016-12-02 2016-12-01 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 52,457 1,828,409 2.95 1.18 62,135 2,165,750
2016-12-02 2016-12-01 4 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		P - Purchase 81,276 2,838,645 2.95 1.18 96,271 3,362,375
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		7,823,083
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		6,841,666
2016-12-02 3 INFI INFINITY PHARMACEUTICALS, INC.
Common Stock, $0.001 par value 		5,598,107
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,850,758
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		3,381,916
2016-09-12 3 XENE Xenon Pharmaceuticals Inc.
Common Stock, no par value per share 		2,761,110
2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock 		A - Award 6,197 6,197 800.00 4,957,600 4,957,600
2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock 		A - Award 1,029 1,029 800.00 823,200 823,200
2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock 		A - Award 4,519 4,519 800.00 3,615,200 3,615,200
2016-06-27 2016-06-23 4 ONTY Cascadian Therapeutics, Inc.
Series D Convertible Preferred Stock 		A - Award 5,505 5,505 800.00 4,404,000 4,404,000
2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 58,613 17,263,200 0.34 1.22 71,338 21,011,041
2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 32,571 3,090,744 1.07 1.22 39,642 3,761,745
2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 90,049 8,850,836 1.03 1.22 109,599 10,772,352
2016-01-11 2016-01-08 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 186,314 15,592,160 1.21 1.22 226,763 18,977,218
2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 8,091 17,204,587 0.05 1.22 9,848 20,939,703
2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 29,655 3,058,173 0.98 1.22 36,093 3,722,102
2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 87,747 8,760,787 1.01 1.22 106,797 10,662,754
2016-01-11 2016-01-07 4 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		P - Purchase 508,287 15,405,846 3.41 1.22 618,636 18,750,455
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		23,547,788
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		21,842,395
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		19,541,857
2015-12-22 3 ONTY Oncothyreon Inc.
Common Stock, no par value per share 		29,064,800
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		58,693,172
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		52,468,653
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		46,824,131
2015-12-14 3 CTIC CTI BIOPHARMA CORP
Common Stock, no par value per share 		60,992,109
2015-11-05 2015-11-05 4 CCXI ChemoCentryx, Inc.
Common Stock 		J - Other -2,384,577 0 -100.00
2015-11-05 2015-11-04 4 CCXI ChemoCentryx, Inc.
Common Stock 		S - Sale -287,000 2,384,577 -10.74 7.00 -2,009,057 16,692,516
2015-11-05 2015-11-03 4 CCXI ChemoCentryx, Inc.
Common Stock 		S - Sale -73,000 2,671,577 -2.66 6.98 -509,343 18,640,394
2015-11-02 2015-11-02 4 CCXI ChemoCentryx, Inc.
Common Stock 		S - Sale -50,000 2,744,577 -1.79 6.97 -348,515 19,130,525
2015-06-11 2015-06-10 4 CCXI ChemoCentryx, Inc.
Common Stock 		S - Sale -31,000 2,794,577 -1.10 9.01 -279,229 25,171,873
2015-06-11 2015-06-09 4 CCXI ChemoCentryx, Inc.
Common Stock 		S - Sale -924,700 2,825,577 -24.66 9.00 -8,322,392 25,430,476
2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Preferred Stock, $0.0001 per share 		J - Other 1,400 1,400
2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Preferred Stock, $0.0001 per share 		J - Other 2,600 2,600
2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		J - Other -1,400,000 1,898,293 -42.45
2015-02-09 2015-02-05 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		J - Other -2,600,000 3,762,683 -40.86
2014-12-17 2014-12-17 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		P - Purchase 55,197 3,298,293 1.70 1.73 95,662 5,716,272
2014-12-17 2014-12-17 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		P - Purchase 98,298 6,362,683 1.57 1.73 170,360 11,027,166
2014-12-17 2014-12-15 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		P - Purchase 79,434 3,243,096 2.51 1.88 149,249 6,093,453
2014-12-17 2014-12-15 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		P - Purchase 145,515 6,264,385 2.38 1.88 273,408 11,770,153
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		15,401,402
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		12,446,194
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		15,401,402
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		12,446,194
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		15,401,402
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		12,446,194
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		15,401,402
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		12,446,194
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		15,401,402
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		12,446,194
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		15,401,402
2014-12-17 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		12,446,194
2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Warrants 		J - Other -242,814 1,223,484 -16.56 1.59 -386,074 1,945,340
2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Warrants 		J - Other -407,136 2,288,698 -15.10 1.59 -647,346 3,639,030
2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		J - Other -258,230 2,412,290 -9.67 3.24 -836,665 7,815,820
2014-07-16 2014-07-16 4 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		J - Other -296,008 4,512,523 -6.16 3.24 -959,066 14,620,575
2014-07-10 2014-07-01 4 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		J - Other -494,092 7,058,997 -6.54 4.56 -2,253,060 32,189,026
2014-07-03 2014-07-01 4 CAPS Capstone Therapeutics Corp.
Common Stock, $0.0005 par value 		J - Other -616,563 3,993,637 -13.37 0.30 -184,969 1,198,091
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		16,369,219
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		14,974,663
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		20,518,746
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		16,369,219
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		14,974,663
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		20,518,746
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		16,369,219
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		14,974,663
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		20,518,746
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		16,369,219
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		14,974,663
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		20,518,746
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		16,369,219
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		14,974,663
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		20,518,746
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		16,369,219
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		14,974,663
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		20,518,746
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		16,369,219
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		14,974,663
2014-07-03 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		20,518,746
2014-03-26 2014-03-25 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -10,203 130,175 -7.27 69.95 -713,734 9,106,171
2014-03-26 2014-03-25 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -18,019 230,125 -7.26 69.95 -1,260,489 16,098,003
2014-03-26 2014-03-24 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -18,306 140,378 -11.54 70.17 -1,284,483 9,849,945
2014-03-26 2014-03-24 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -31,698 248,144 -11.33 70.17 -2,224,163 17,411,594
2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Preferred Stock, $0.001 per share 		J - Other 2,632 2,632
2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Preferred Stock, $0.001 per share 		J - Other 4,577 4,577
2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Common Stock, $0.001 par value 		J - Other -526,436 1,121,221 -31.95
2014-03-25 2014-03-21 4 RGDO Regado Biosciences Inc
Common Stock, $0.001 par value 		J - Other -915,345 1,979,670 -31.62
2014-03-03 2014-02-27 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -200,827 2,494,521 -7.45 1.09 -218,901 2,719,028
2014-03-03 2014-02-27 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -33,610 438,127 -7.12 1.09 -36,635 477,558
2014-03-03 2014-02-27 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -59,388 772,480 -7.14 1.09 -64,733 842,003
2014-02-26 2014-02-26 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -33,236 2,695,348 -1.22 1.11 -36,869 2,989,950
2014-02-26 2014-02-26 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -4,416 471,737 -0.93 1.11 -4,899 523,298
2014-02-26 2014-02-26 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -7,745 831,868 -0.92 1.11 -8,592 922,791
2014-02-26 2014-02-25 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -151,535 2,728,584 -5.26 1.12 -169,659 3,054,923
2014-02-26 2014-02-25 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -25,060 476,153 -5.00 1.12 -28,057 533,101
2014-02-26 2014-02-25 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -44,147 839,613 -5.00 1.12 -49,427 940,031
2014-02-26 2014-02-24 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -191,804 2,880,119 -6.24 1.16 -222,838 3,346,122
2014-02-26 2014-02-24 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -29,710 501,213 -5.60 1.16 -34,517 582,309
2014-02-26 2014-02-24 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -52,528 883,760 -5.61 1.16 -61,027 1,026,752
2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -5,359 79,390 -6.32 73.05 -391,464 5,799,273
2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -112,369 1,685,344 -6.25 73.05 -8,208,319 123,110,840
2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -10,557 158,684 -6.24 73.05 -771,167 11,591,533
2014-02-20 2014-02-20 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -18,615 279,842 -6.24 73.05 -1,359,787 20,441,870
2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -2,771 84,749 -3.17 73.03 -202,375 6,189,499
2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -57,370 1,797,713 -3.09 73.03 -4,189,920 131,292,913
2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -5,395 169,241 -3.09 73.03 -394,015 12,360,229
2014-02-20 2014-02-19 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -9,464 298,457 -3.07 73.03 -691,187 21,797,300
2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -14,003 87,520 -13.79 74.66 -1,045,409 6,533,902
2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -153,751 1,855,083 -7.65 74.66 -11,478,450 138,493,262
2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -16,331 174,636 -8.55 74.66 -1,219,209 13,037,643
2014-02-20 2014-02-18 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock, $0.001 par value 		S - Sale -16,915 307,921 -5.21 74.66 -1,262,808 22,988,181
2014-02-19 2014-02-19 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -19,077 3,071,923 -0.62 1.11 -21,216 3,416,286
2014-02-19 2014-02-19 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -10,470 530,923 -1.93 1.11 -11,644 590,439
2014-02-19 2014-02-19 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -14,059 936,288 -1.48 1.11 -15,635 1,041,246
2014-02-19 2014-02-18 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -110,885 541,393 -17.00 1.18 -130,623 637,761
2014-02-19 2014-02-18 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -122,443 950,347 -11.41 1.18 -144,238 1,119,509
2014-02-19 2014-02-14 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -15,622 652,278 -2.34 1.16 -18,139 757,360
2014-02-19 2014-02-14 4 PTN PALATIN TECHNOLOGIES INC
Common Stock, par value $.01 per share 		S - Sale -13,410 1,072,790 -1.23 1.16 -15,570 1,245,616
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		5,080,487
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		4,222,129
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		5,080,487
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		4,222,129
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		5,080,487
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		4,222,129
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		5,080,487
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		4,222,129
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		5,080,487
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		4,222,129
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		5,080,487
2014-02-10 3 RGDO Regado Biosciences Inc
Common stock, $0.001 par value 		4,222,129
2013-12-05 2013-12-05 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 41,451 1,251,914 3.42 5.03 208,358 6,292,871
2013-12-05 2013-12-05 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 82,849 2,162,381 3.98 5.03 416,449 10,869,424
2013-12-05 2013-12-03 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 16,175 1,210,463 1.35 4.98 80,590 6,031,011
2013-12-05 2013-12-03 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 49,325 2,079,532 2.43 4.98 245,757 10,361,060
2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -154,578 2,008,834 -7.15 57.07 -8,822,493 114,653,598
2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -27,058 101,523 -21.04 57.07 -1,544,327 5,794,395
2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -50,934 190,967 -21.06 57.07 -2,907,043 10,899,384
2013-11-29 2013-11-27 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -86,435 324,836 -21.02 57.07 -4,933,252 18,539,917
2013-11-29 2013-11-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -34,917 128,581 -21.36 57.57 -2,010,172 7,402,408
2013-11-29 2013-11-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -54,444 241,901 -18.37 57.57 -3,134,341 13,926,241
2013-11-29 2013-11-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -119,139 411,271 -22.46 57.57 -6,858,832 23,676,871
2013-11-20 2013-11-19 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock 		S - Sale -153,056 646,559 -19.14 2.64 -404,343 1,708,080
2013-11-20 2013-11-19 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock 		S - Sale -331,566 1,123,848 -22.78 2.64 -875,931 2,968,982
2013-11-06 2013-11-06 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 8,371 1,194,288 0.71 4.69 39,235 5,597,628
2013-11-06 2013-11-06 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 11,985 2,030,207 0.59 4.69 56,174 9,515,580
2013-11-06 2013-11-05 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 74,684 1,185,917 6.72 4.97 370,978 5,890,806
2013-11-06 2013-11-05 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 35,526 2,018,222 1.79 4.97 176,468 10,025,114
2013-11-06 2013-11-04 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 5,500 1,111,233 0.50 4.90 26,944 5,443,819
2013-11-05 2013-11-01 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 79,360 2,670,520 3.06 1.78 141,261 4,753,526
2013-11-05 2013-11-01 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 49,640 4,808,531 1.04 1.78 88,359 8,559,185
2013-11-01 2013-11-01 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 25,154 1,105,733 2.33 4.92 123,775 5,440,980
2013-11-01 2013-11-01 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 45,406 1,982,696 2.34 4.92 223,429 9,756,252
2013-11-01 2013-10-31 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 44,584 1,080,579 4.30 4.97 221,373 5,365,399
2013-11-01 2013-10-31 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 79,998 1,937,290 4.31 4.97 397,214 9,619,226
2013-11-01 2013-10-30 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 50,339 1,035,995 5.11 5.04 253,693 5,221,104
2013-11-01 2013-10-30 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 90,744 1,857,292 5.14 5.04 457,323 9,360,194
2013-10-10 2013-10-09 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 29,564 985,656 3.09 5.26 155,445 5,182,481
2013-10-10 2013-10-09 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 53,271 1,766,548 3.11 5.26 280,094 9,288,333
2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 401,675 956,092 72.45 5.35 2,148,961 5,115,092
2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 30,406 554,417 5.80 5.31 161,310 2,941,293
2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 726,626 1,713,277 73.65 5.35 3,887,449 9,166,032
2013-10-10 2013-10-08 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 47,812 986,651 5.09 5.31 253,652 5,234,381
2013-10-07 2013-10-03 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 38,599 524,011 7.95 5.49 212,071 2,879,021
2013-10-07 2013-10-03 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 70,826 938,839 8.16 5.49 389,132 5,158,169
2013-09-25 2013-09-23 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -147,806 296,345 -33.28 44.50 -6,577,367 13,187,352
2013-09-25 2013-09-23 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		S - Sale -211,217 530,410 -28.48 44.50 -9,399,156 23,603,245
2013-09-13 2013-09-13 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 3,370 485,412 0.70 6.09 20,520 2,955,722
2013-09-13 2013-09-13 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 6,307 868,013 0.73 6.09 38,404 5,285,418
2013-09-13 2013-09-11 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 105,892 482,042 28.15 5.94 629,136 2,863,956
2013-09-13 2013-09-11 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 210,066 861,706 32.24 5.94 1,248,065 5,119,654
2013-08-12 2013-08-08 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 177,940 2,591,160 7.37 1.65 293,512 4,274,118
2013-08-12 2013-08-08 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 80,421 4,758,891 1.72 1.65 132,654 7,849,791
2013-08-02 2013-08-01 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 35,703 2,413,220 1.50 1.78 63,651 4,302,289
2013-08-02 2013-08-01 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 122,641 4,678,470 2.69 1.78 218,644 8,340,776
2013-08-02 2013-07-31 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 179,743 4,555,829 4.11 1.71 307,307 7,789,101
2013-06-11 2013-06-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock 		P - Purchase 8,102 799,615 1.02 3.47 28,095 2,772,825
2013-06-11 2013-06-07 4 RIGL RIGEL PHARMACEUTICALS INC
Common Stock 		P - Purchase 24,598 1,455,414 1.72 3.47 85,298 5,046,939
2013-06-07 2013-06-07 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 41,526 2,377,517 1.78 1.83 76,009 4,351,807
2013-06-07 2013-06-07 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 74,726 4,376,086 1.74 1.83 136,778 8,009,988
2013-06-07 2013-06-06 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 27,384 2,335,991 1.19 1.78 48,768 4,160,166
2013-06-07 2013-06-06 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 55,531 4,301,360 1.31 1.78 98,895 7,660,292
2013-06-07 2013-06-05 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 5,000 2,308,607 0.22 1.75 8,750 4,040,062
2013-06-07 2013-06-05 4 ONTY Oncothyreon Inc.
Common Stock 		P - Purchase 10,300 4,245,829 0.24 1.75 18,025 7,430,201
2013-06-07 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		4,235,529
2013-06-07 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		2,303,607
2013-06-07 3 ONTY Oncothyreon Inc.
Common Stock, $0.0001 par value 		1,298,842
2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 		1,430,816
2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 		791,513
2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 		6,962,123
2013-05-15 3 RIGL RIGEL PHARMACEUTICALS INC
Common Stock, $0.001 par value 		513,545
2013-01-25 2013-01-23 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		P - Purchase 39,600 2,163,412 1.86 19.78 783,181 42,786,448
2012-12-18 2012-12-14 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		P - Purchase 5,386 2,123,812 0.25 18.63 100,365 39,575,962
2012-12-10 2012-12-06 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		P - Purchase 50,100 2,118,426 2.42 17.94 898,959 38,011,553
2012-11-20 2012-11-16 4/A TRGT TARGACEPT INC
Common Stock 		P - Purchase 217,000 1,713,907 14.50 4.00 867,935 6,855,114
2012-11-20 2012-11-16 4/A TRGT TARGACEPT INC
Common Stock 		P - Purchase 378,000 2,977,919 14.54 4.00 1,511,887 11,910,783
2012-11-19 2012-11-16 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 26,800 1,523,707 1.79 5.11 136,902 7,783,552
2012-11-19 2012-11-16 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 46,700 2,646,619 1.80 5.11 238,558 13,519,724
2012-11-19 2012-11-14 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 444,649 1,496,907 42.26 4.00 1,778,596 5,987,628
2012-11-19 2012-11-14 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 772,063 2,599,919 42.24 4.00 3,088,252 10,399,676
2012-11-19 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		790,501
2012-11-19 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		456,746
2012-11-19 3 ARRY ARRAY BIOPHARMA INC
Common Stock, $0.001 par value 		9,894,589
2012-11-19 2012-11-06 4/A CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 40,000 3,750,277 1.08 12.00 479,828 44,987,198
2012-11-19 2012-10-31 4/A LGND LIGAND PHARMACEUTICALS INC
Common Stock 		P - Purchase 4,076 741,627 0.55 14.99 61,096 11,116,395
2012-11-19 2012-10-26 4/A LGND LIGAND PHARMACEUTICALS INC
Common Stock 		P - Purchase 12,515 737,551 1.73 15.26 190,926 11,251,931
2012-11-09 2012-11-08 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 17,400 1,052,258 1.68 4.01 69,718 4,216,187
2012-11-09 2012-11-08 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 31,929 1,827,856 1.78 4.01 127,933 7,323,853
2012-11-09 2012-11-07 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 8,800 1,034,858 0.86 4.08 35,915 4,223,462
2012-11-09 2012-11-07 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 14,300 1,795,927 0.80 4.08 58,361 7,329,537
2012-11-08 2012-11-06 4 CCXI ChemoCentryx, Inc.
Common Stock 		P - Purchase 40,000 3,750,277 1.08 12.00 479,828 44,987,198
2012-11-02 2012-10-31 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		P - Purchase 4,076 741,627 0.55 14.99 61,096 11,116,395
2012-11-02 2012-10-26 4 LGND LIGAND PHARMACEUTICALS INC
Common Stock 		P - Purchase 12,515 737,551 1.73 15.26 190,926 11,251,931
2012-11-02 2012-11-02 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 21,500 1,026,058 2.14 4.05 87,150 4,159,126
2012-11-02 2012-11-02 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 36,100 1,781,627 2.07 4.05 146,331 7,221,825
2012-11-02 2012-11-01 4 TRGT TARGACEPT INC
CommonStock 		P - Purchase 23,400 1,004,558 2.38 4.05 94,688 4,064,944
2012-11-02 2012-11-01 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 6,700 1,745,527 0.39 4.05 27,112 7,063,275
2012-11-02 2012-10-31 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 5,300 981,158 0.54 4.06 21,495 3,979,283
2012-11-02 2012-10-31 4 TRGT TARGACEPT INC
Common Stock 		P - Purchase 46,700 1,738,827 2.76 4.06 189,401 7,052,161
2012-09-10 3 TRGT TARGACEPT INC
Common Stock, $0.001 par value 		1,692,127
2012-09-10 3 TRGT TARGACEPT INC
Common Stock, $0.001 par value 		975,858
2012-09-10 3 TRGT TARGACEPT INC
Common Stock, $0.001 par value 		349,482
2012-08-31 3 CCXI ChemoCentryx, Inc.
Common Stock, $0.001 par value 		651,640
2012-08-31 3 CCXI ChemoCentryx, Inc.
Common Stock, $0.001 par value 		376,150
2012-08-31 3 CCXI ChemoCentryx, Inc.
Common Stock, $0.001 par value 		3,710,277
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)